uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.1326 | Q34 | What are the names of the genes that are targeted by the drug Lorlatinib in the treatment of cancer? | In the context of cancer, the drug Lorlatinib targets the gene ALK receptor tyrosine kinase and EMAP like 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%lorlatinib%" OR LOWER(tradeNames_list) LIKE "%lorlatinib%" OR LOWER(syns_list) LIKE "%lorlatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_991068', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991092', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991100', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991108', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991124', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991132', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991140', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991156', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991164', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991172', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991180', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991196', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991204', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991212', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991220', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991228', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991236', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991244', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991252', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991260', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991148', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991084', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991052', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991036', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991028', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991188', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_991116', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991076', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991060', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_991044', 'drugName': 'Lorlatinib', 'tradeNames_list': "['Lorbrena']", 'syns_list': "['Lorlatinib', 'PF-06463922']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.246 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of frozen shoulder? | In the context of frozen shoulder, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%frozen shoulder%" OR LOWER(efo_term) LIKE "%frozen shoulder%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222206', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222336', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222076', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221946', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221881', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222271', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222141', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222011', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.635 | Q34 | What are the names of the genes that are targeted by the drug Axitinib in the treatment of cancer? | In the context of cancer, the drug Axitinib targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1 and fms related receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%axitinib%" OR LOWER(tradeNames_list) LIKE "%axitinib%" OR LOWER(syns_list) LIKE "%axitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_689447', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689993', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689951', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689573', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689237', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689321', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689825', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689657', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689909', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689783', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689741', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690035', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689531', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689153', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689195', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689615', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690119', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689363', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689405', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689867', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689279', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_690077', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689489', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689699', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_690076', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689488', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689614', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689446', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689908', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689530', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689320', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689824', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690034', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690118', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689362', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689278', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689656', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689782', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689236', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689194', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689404', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689572', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689992', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689152', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689950', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689866', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689698', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689740', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Kidney Neoplasms', 'efo_term': 'kidney cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689484', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689313', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689314', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689565', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689229', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689316', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689566', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689523', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689944', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689482', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689524', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689526', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689608', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689145', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689148', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689649', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689146', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689943', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689946', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689397', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689652', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689398', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689776', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689440', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689691', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689692', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689860', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689694', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689734', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689733', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689190', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689400', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689271', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689272', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689274', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689736', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689188', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689862', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689439', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689442', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689775', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689650', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689778', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689901', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689610', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689902', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689904', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689817', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689818', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689481', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689820', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689230', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.576 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of hemorrhoid? | In the context of hemorrhoid, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhoid%" OR LOWER(efo_term) LIKE "%hemorrhoid%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_640896', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641011', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_639516', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_641816', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639056', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_642506', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_639976', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637906', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_643771', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_644231', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_638596', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_643311', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_642621', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642161', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_644116', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_638826', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_640781', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641241', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_642391', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_644461', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_640206', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640666', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642966', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_641126', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_642736', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643196', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642276', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642851', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637791', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638941', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638021', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639286', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638251', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_639746', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638481', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638711', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_641701', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639401', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_641471', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_640551', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_638366', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_641586', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_643081', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642046', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_639631', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_644001', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_639861', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_641931', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640091', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_638136', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_643886', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_644346', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644576', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_640436', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_643541', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_641356', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639171', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_640321', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_643426', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643656', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637178', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_636898', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636918', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636958', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637038', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637198', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637478', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637538', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637218', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637558', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637058', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637238', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637598', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_637258', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637638', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637658', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636978', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637078', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637278', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_637678', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637618', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_637298', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637098', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637318', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637338', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637578', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636938', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636998', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637118', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_637358', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_637518', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637378', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637138', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637398', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637418', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637018', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_637158', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_637438', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_637458', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_637498', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'syns_list': "['Anhydrous lidocaine hydrochloride', 'Lidocaine hclLidocaine hydrochloride', 'Lidocaine hydrochloride anhydrousLidocaine hydrochloride monohydrate', 'Lidocaine hydrochloride uspLidocaini hydrochloridum', 'Lignocaine (as hydrochloride)Lignocaine hydrochloride', 'NSC-757420', 'Xylocaine hydrochloride']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.791 | Q34 | What are the names of the genes that are targeted by the drug Niraparib Tosylate in the treatment of ovarian carcinoma? | In the context of ovarian carcinoma, the drug Niraparib Tosylate targets the gene poly(ADP-ribose) polymerase 2 and poly(ADP-ribose) polymerase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ovarian carcinoma%" OR LOWER(efo_term) LIKE "%ovarian carcinoma%") AND (LOWER(drugName) LIKE "%niraparib tosylate%" OR LOWER(tradeNames_list) LIKE "%niraparib tosylate%" OR LOWER(syns_list) LIKE "%niraparib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823354', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823366', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823370', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823374', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823362', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823346', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823338', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823334', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823378', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823358', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP1', 'approvedName': 'poly(ADP-ribose) polymerase 1'}, {'UUID': 'DrugTargetsIndication121923_text_823350', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_823342', 'drugName': 'Niraparib Tosylate', 'tradeNames_list': "['Zejula']", 'syns_list': "['MK-4827-TOSYLATE', 'Niraparib tosylate', 'Niraparib tosylate anhydrousNiraparib tosylate monohydrate']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian carcinoma', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.468 | Q34 | What are the names of the genes that are targeted by the drug Oxymetazoline Hydrochloride in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Oxymetazoline Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%oxymetazoline hydrochloride%" OR LOWER(tradeNames_list) LIKE "%oxymetazoline hydrochloride%" OR LOWER(syns_list) LIKE "%oxymetazoline hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_417211', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417230', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417231', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417240', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417250', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417251', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417260', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417270', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417271', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417280', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417281', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417291', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417300', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417301', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417310', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417311', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417320', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417321', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417330', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417331', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417340', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417350', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417351', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417360', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417361', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417370', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417380', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417381', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417390', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417391', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417400', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417401', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417410', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417411', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417420', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417421', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417430', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417431', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417440', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417441', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417450', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417451', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417460', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417461', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417470', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417471', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417480', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417481', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417490', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417491', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417500', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417510', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417511', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417520', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417521', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417530', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417531', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417541', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417550', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417551', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417560', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417561', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417570', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417571', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417580', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417581', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417590', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417591', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417600', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417601', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417610', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417611', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417620', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417621', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417630', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417631', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417640', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417641', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417650', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417651', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417660', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417661', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417670', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417671', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417680', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417681', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417501', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417341', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417261', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417221', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417201', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417191', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417190', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417540', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417371', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417290', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417241', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417220', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417210', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417200', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.879 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac in the treatment of Dysmenorrhea? | In the context of Dysmenorrhea, the drug Diclofenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%dysmenorrhea%" OR LOWER(efo_term) LIKE "%dysmenorrhea%") AND (LOWER(drugName) LIKE "%diclofenac%" OR LOWER(tradeNames_list) LIKE "%diclofenac%" OR LOWER(syns_list) LIKE "%diclofenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_837545', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836975', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837815', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837605', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837125', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837275', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837335', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837845', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837935', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837005', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837725', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837035', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837755', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837095', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837875', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837245', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837665', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837065', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837515', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837395', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837365', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837215', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837155', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837995', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838025', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837485', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837785', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837905', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837425', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837185', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837635', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837455', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837965', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837305', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837575', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837695', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842886', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842904', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842913', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842922', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842931', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842940', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_843048', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842949', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842958', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842967', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842976', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842985', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_842895', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842994', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843003', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843012', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843021', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843030', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843039', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_843057', 'drugName': 'Diclofenac Potassium', 'tradeNames_list': "['Cambia', 'Cataflam', 'Diclofenac potassium', 'Voltarol joint painVoltarol pain-eze', 'Voltarol pain-eze extra strgh', 'Voltarol rapidZipsor']", 'syns_list': "['CGP 45840B', 'CGP-45840B', 'Diclofenac potassiumDiclofenac potassium salt', 'Potassium diclofenac']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1920 | Q34 | What are the names of the genes that are targeted by the drug Bempedoic Acid in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Bempedoic Acid targets the gene ATP citrate lyase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%bempedoic acid%" OR LOWER(tradeNames_list) LIKE "%bempedoic acid%" OR LOWER(syns_list) LIKE "%bempedoic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191840', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191808', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191800', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191824', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191832', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}, {'UUID': 'DrugTargetsIndication121923_text_1191816', 'drugName': 'Bempedoic Acid', 'tradeNames_list': "['Nexletol']", 'syns_list': "['Bempedoic acid', 'ESP-55016', 'ETC-1002', 'ETC1002']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'ACLY', 'approvedName': 'ATP citrate lyase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1270 | Q34 | What are the names of the genes that are targeted by the drug Megestrol Acetate in the treatment of neoplasm? | In the context of neoplasm, the drug Megestrol Acetate targets the gene progesterone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%megestrol acetate%" OR LOWER(tradeNames_list) LIKE "%megestrol acetate%" OR LOWER(syns_list) LIKE "%megestrol acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940534', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940576', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940598', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940513', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940514', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940577', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940597', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940556', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940555', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940535', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940591', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940529', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940546', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940548', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial carcinoma', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940572', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940550', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940507', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940530', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940551', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940570', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940506', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial carcinoma', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940526', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940571', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940525', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940528', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940509', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940567', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940592', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940588', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940590', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial carcinoma', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940593', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940527', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial carcinoma', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940504', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940589', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940508', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940549', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Liver Neoplasms', 'efo_term': 'liver cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940547', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940569', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial carcinoma', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940568', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940505', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940499', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940561', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940562', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940564', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940540', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940582', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940583', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940585', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940501', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940498', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940519', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine neoplasm', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940541', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940543', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940520', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940522', 'drugName': 'Megestrol Acetate', 'tradeNames_list': "['Megace', 'Megace es', 'Megestrol acetate', 'Ovaban']", 'syns_list': "['5071', 'BDH 1298', 'BDH-1298', 'Chronopil', 'Megesterol acetate', 'MegestrolMegestrol 17.alpha.-acetate', 'Megestrol acetate', 'NSC-71423', 'SC 10363SC-10363']", 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Uterine Neoplasms', 'efo_term': 'uterine cancer', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.418 | Q34 | What are the names of the genes that are targeted by the drug Fenofibrate in the treatment of Abnormal circulating lipid concentration? | In the context of Abnormal circulating lipid concentration, the drug Fenofibrate targets the gene peroxisome proliferator activated receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%abnormal circulating lipid concentration%" OR LOWER(efo_term) LIKE "%abnormal circulating lipid concentration%") AND (LOWER(drugName) LIKE "%fenofibrate%" OR LOWER(tradeNames_list) LIKE "%fenofibrate%" OR LOWER(syns_list) LIKE "%fenofibrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_244082', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244169', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244198', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244227', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244285', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244314', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244343', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244401', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244430', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244372', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244140', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243966', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243937', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244024', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244256', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244111', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244053', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243995', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.275 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Furoate in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Fluticasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%fluticasone furoate%" OR LOWER(tradeNames_list) LIKE "%fluticasone furoate%" OR LOWER(syns_list) LIKE "%fluticasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225658', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225685', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225694', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225703', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225721', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225730', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225739', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225757', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225766', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225775', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225784', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225802', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225811', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225820', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225829', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225838', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225847', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225856', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225865', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225874', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225883', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225901', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225910', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225919', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225928', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225937', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225955', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225964', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225973', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225982', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225991', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226000', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226009', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226018', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226027', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226036', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226045', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226054', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226063', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226072', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226081', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226090', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226099', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225892', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225748', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225676', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225640', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225622', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225613', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225946', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225793', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225712', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225667', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225649', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225631', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1885 | Q34 | What are the names of the genes that are targeted by the drug Cinacalcet Hydrochloride in the treatment of carcinoma? | In the context of carcinoma, the drug Cinacalcet Hydrochloride targets the gene calcium sensing receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%carcinoma%" OR LOWER(efo_term) LIKE "%carcinoma%") AND (LOWER(drugName) LIKE "%cinacalcet hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cinacalcet hydrochloride%" OR LOWER(syns_list) LIKE "%cinacalcet hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149031', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149021', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149009', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149024', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149016', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149036', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149019', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149026', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149034', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149011', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Parathyroid Neoplasms', 'efo_term': 'Parathyroid Gland Carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149029', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149014', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma', 'efo_term': 'carcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149023', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149018', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149008', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149013', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149033', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149028', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_list': "['Mimpara', 'Sensipar']", 'syns_list': "['AMG-073', 'AMG-073 HCL', 'AMG073 HCL', 'AMG073 HYDROCHLORIDECinacalcet hcl', 'Cinacalcet hydrochloride']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'CASR', 'approvedName': 'calcium sensing receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1981 | Q34 | What are the names of the genes that are targeted by the drug Selinexor in the treatment of neoplasm? | In the context of neoplasm, the drug Selinexor targets the gene exportin 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%selinexor%" OR LOWER(tradeNames_list) LIKE "%selinexor%" OR LOWER(syns_list) LIKE "%selinexor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1194811', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194055', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194223', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194685', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193845', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195609', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194979', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193885', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194473', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193801', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195273', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195357', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194725', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195567', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195525', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194181', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193719', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195649', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194265', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193717', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195019', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194389', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194307', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194349', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195187', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194433', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193929', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195355', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194643', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194641', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194599', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195397', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193969', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195439', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194139', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195607', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194809', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195565', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193843', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194895', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193761', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194013', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194557', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195021', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194263', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194937', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194935', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195693', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194977', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195691', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195651', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193887', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194475', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193759', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195105', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194011', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195103', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195231', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194391', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195147', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194431', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195229', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193927', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195189', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193803', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195483', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194515', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194769', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194517', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195315', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194559', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195313', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194601', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195481', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194767', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194683', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193971', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195441', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195399', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194727', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194137', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194853', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194179', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195523', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195271', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195145', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195063', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194305', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194851', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194893', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194347', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194053', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194097', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195061', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194221', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194095', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195060', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1194262', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1195018', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193884', 'drugName': 'Selinexor', 'tradeNames_list': "['Xpovio']", 'syns_list': "['KPT-330', 'Selinexor']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'XPO1', 'approvedName': 'exportin 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1440 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Benzoate in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Amlodipine Benzoate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%amlodipine benzoate%" OR LOWER(tradeNames_list) LIKE "%amlodipine benzoate%" OR LOWER(syns_list) LIKE "%amlodipine benzoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1044027', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044045', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044051', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044057', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044069', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044075', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044081', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044093', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044099', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044105', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044111', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044123', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044129', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044135', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044141', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044147', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044153', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044159', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044165', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044171', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044177', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044183', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044087', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044039', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044015', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044003', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043997', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044117', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044063', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044033', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044021', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044009', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.252 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of anemia? | In the context of anemia, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anemia%" OR LOWER(efo_term) LIKE "%anemia%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222212', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222342', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222082', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221952', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221887', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222277', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222147', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222017', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.416 | Q34 | What are the names of the genes that are targeted by the drug Fenofibric Acid in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Fenofibric Acid targets the gene peroxisome proliferator activated receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%fenofibric acid%" OR LOWER(tradeNames_list) LIKE "%fenofibric acid%" OR LOWER(syns_list) LIKE "%fenofibric acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243843', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243861', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243867', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243873', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243885', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243891', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243897', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243903', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243855', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243831', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243819', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243813', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243879', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243849', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243837', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243825', 'drugName': 'Fenofibric Acid', 'tradeNames_list': "['Fenocor-67', 'Fenogal', 'Fibricor', 'Lipanthyl', 'Lipofen', 'LofibraSupralip', 'Trilipix']", 'syns_list': "['Fenofibrate free acid', 'Fenofibrate related compound bFenofibric acid', 'LF-153', 'NSC-281318', 'Procetofenic acid']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.595 | Q34 | What are the names of the genes that are targeted by the drug Lamotrigine in the treatment of Bilateral tonic-clonic seizure? | In the context of Bilateral tonic-clonic seizure, the drug Lamotrigine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bilateral tonic-clonic seizure%" OR LOWER(efo_term) LIKE "%bilateral tonic-clonic seizure%") AND (LOWER(drugName) LIKE "%lamotrigine%" OR LOWER(tradeNames_list) LIKE "%lamotrigine%" OR LOWER(syns_list) LIKE "%lamotrigine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_653149', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653242', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653273', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653304', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653366', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653397', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653428', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653490', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653521', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653552', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653583', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653645', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653676', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653707', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653738', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653769', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653800', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653831', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653862', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653893', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653924', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653986', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654017', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654048', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654079', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654110', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654172', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654203', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654234', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654265', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654296', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654327', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654358', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654389', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654420', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654451', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654482', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654513', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654544', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654575', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654606', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654637', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654668', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654699', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654730', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654761', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654792', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654823', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654854', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654885', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654916', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654978', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655009', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655040', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655071', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655102', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655133', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655195', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_655226', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655257', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655288', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655319', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655350', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655381', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655412', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655443', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655474', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655505', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655536', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655567', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_655598', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655629', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655660', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655691', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655722', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655753', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655784', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655815', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655846', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655877', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655908', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655939', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_655970', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656001', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656032', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_656063', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_654947', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_653955', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653459', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653211', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653087', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653025', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652994', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_655164', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_654141', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_653614', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653335', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653180', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653118', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653056', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1292 | Q34 | What are the names of the genes that are targeted by the drug Alectinib in the treatment of neoplasm? | In the context of neoplasm, the drug Alectinib targets the gene ret proto-oncogene, ALK receptor tyrosine kinase and EMAP like 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%alectinib%" OR LOWER(tradeNames_list) LIKE "%alectinib%" OR LOWER(syns_list) LIKE "%alectinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_945671', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945651', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945784', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945823', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945842', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945614', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945594', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945689', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945880', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945728', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945633', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945803', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945861', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945804', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945765', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945785', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945860', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945708', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945727', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945690', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945652', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945879', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945709', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945747', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945822', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945841', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945746', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945766', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945595', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945613', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945632', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945670', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945661', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945686', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945684', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945682', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945681', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945680', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945675', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945585', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945588', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945599', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945608', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945701', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945642', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945702', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945622', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945662', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945663', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945679', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945668', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945706', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945667', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945683', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945743', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945740', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945665', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945664', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945738', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945623', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945644', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945603', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945713', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945717', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945724', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945624', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945625', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945589', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945587', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945604', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945719', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945720', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945721', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945611', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945646', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945645', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945718', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945648', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945626', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945627', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945610', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945737', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Brain Neoplasms', 'efo_term': 'brain neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945739', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945741', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945744', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945705', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945643', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945703', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945649', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945722', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'upper aerodigestive tract neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945725', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945618', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945592', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945656', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945732', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'papillary thyroid carcinoma', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945736', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945660', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Salivary Gland Neoplasms', 'efo_term': 'salivary gland neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945605', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Pancreatic Neoplasms', 'efo_term': 'pancreatic neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945629', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Bronchial Neoplasms', 'efo_term': 'bronchial neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945630', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung neoplasm', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1544 | Q34 | What are the names of the genes that are targeted by the drug Cannabidiol in the treatment of Lennox-Gastaut syndrome? | In the context of Lennox-Gastaut syndrome, the drug Cannabidiol targets the gene cannabinoid receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lennox-gastaut syndrome%" OR LOWER(efo_term) LIKE "%lennox-gastaut syndrome%") AND (LOWER(drugName) LIKE "%cannabidiol%" OR LOWER(tradeNames_list) LIKE "%cannabidiol%" OR LOWER(syns_list) LIKE "%cannabidiol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1073764', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073983', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074056', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074129', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074275', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074348', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074421', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074567', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074640', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074713', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074786', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074932', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075005', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075078', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075151', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075224', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075297', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075370', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075443', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075516', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075589', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075735', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075808', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075881', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075954', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076027', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076173', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076246', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076319', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1075662', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074494', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073910', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073618', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073472', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073399', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1076100', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074859', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1074202', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073837', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073691', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073545', 'drugName': 'Cannabidiol', 'tradeNames_list': "['Epidiolex']", 'syns_list': "['(-)-cannabidiol', '(-)-cbd', '(-)-trans-cannabidiol.delta.1(2)-trans-cannabidiol', 'BTX-1204', 'BTX-1503', 'CBD', 'CannabidiolCannabidiol solution', 'Cardiolrx', 'GWP-42003', 'GWP-42003-P', 'GWP42003GWP42003-P']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lennox Gastaut Syndrome', 'efo_term': 'Lennox-Gastaut syndrome', 'approvedSymbol': 'CNR1', 'approvedName': 'cannabinoid receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.312 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of contact dermatitis? | In the context of contact dermatitis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%contact dermatitis%" OR LOWER(efo_term) LIKE "%contact dermatitis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227768', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228623', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228908', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229193', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229763', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230048', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230333', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230903', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231188', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231473', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231758', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232328', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230618', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228338', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227198', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226628', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226343', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232043', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229478', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228053', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227483', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226913', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Contact', 'efo_term': 'contact dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1579 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of pulmonary neuroendocrine tumor? | In the context of pulmonary neuroendocrine tumor, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary neuroendocrine tumor%" OR LOWER(efo_term) LIKE "%pulmonary neuroendocrine tumor%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085637', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086042', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086177', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086312', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086582', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086717', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086852', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087122', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087257', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087392', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087527', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087797', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087932', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088067', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088202', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088337', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088472', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088607', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088742', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088877', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089012', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089282', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089417', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089552', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089687', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089822', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090092', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090227', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090362', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090497', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090632', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089147', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086987', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085907', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085367', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085097', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084962', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089957', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087662', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086447', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085772', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085502', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085232', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.383 | Q34 | What are the names of the genes that are targeted by the drug Mometasone Furoate in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Mometasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%mometasone furoate%" OR LOWER(tradeNames_list) LIKE "%mometasone furoate%" OR LOWER(syns_list) LIKE "%mometasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_242037', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242115', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242141', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242167', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242219', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242089', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241985', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241933', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241907', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242193', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242063', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_242011', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241959', 'drugName': 'Mometasone Furoate', 'tradeNames_list': "['Asmanex', 'Asmanex hfa', 'Asmanex twisthaler', 'EloconMometasone furoate', 'Nasonex', 'Nasonex 24hr allergy', 'Sinuva']", 'syns_list': "['LAS-41002', 'LAS41002', 'LYR-210', 'LYR210', 'Lyr-210', 'MometasoneMometasone furoate', 'Mometasone furoate anhydrousMometasone furoate hydrate', 'Mometasone furoate monohydrate', 'MonovoNSC-746171', 'NSC-760077', 'Nasonex', 'SCH 32088', 'SCH-32088']", 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1686 | Q34 | What are the names of the genes that are targeted by the drug Empagliflozin in the treatment of diabetes mellitus? | In the context of diabetes mellitus, the drug Empagliflozin targets the gene solute carrier family 5 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes mellitus%" OR LOWER(efo_term) LIKE "%diabetes mellitus%") AND (LOWER(drugName) LIKE "%empagliflozin%" OR LOWER(tradeNames_list) LIKE "%empagliflozin%" OR LOWER(syns_list) LIKE "%empagliflozin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096709', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096683', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096547', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096466', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096763', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096467', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096682', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096385', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096790', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096440', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096548', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096412', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096628', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096520', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096602', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096493', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096413', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096629', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096736', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096574', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096494', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096656', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096710', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096764', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096791', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096655', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096737', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096386', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096601', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096439', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096521', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096575', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096384', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096519', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096681', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096546', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096465', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096735', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096762', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096708', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096411', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096573', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096789', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096438', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096492', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096600', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096627', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096654', 'drugName': 'Empagliflozin', 'tradeNames_list': "['Bi 10773', 'Jardiance']", 'syns_list': "['BI 10773', 'BI-10773', 'Bi10773', 'Empagliflozin']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.428 | Q34 | What are the names of the genes that are targeted by the drug Selexipag in the treatment of Recurrent thrombophlebitis? | In the context of Recurrent thrombophlebitis, the drug Selexipag targets the gene prostaglandin I2 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%recurrent thrombophlebitis%" OR LOWER(efo_term) LIKE "%recurrent thrombophlebitis%") AND (LOWER(drugName) LIKE "%selexipag%" OR LOWER(tradeNames_list) LIKE "%selexipag%" OR LOWER(syns_list) LIKE "%selexipag%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_246143', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246155', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246159', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246163', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246171', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246175', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246179', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246187', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246191', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246195', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246199', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246207', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246211', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246215', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246219', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246223', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246227', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246231', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246235', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246239', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246243', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246251', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246255', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246259', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246263', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246267', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246275', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246279', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246283', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246287', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246291', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246295', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246299', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246303', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246307', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246311', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246315', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246319', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246323', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246327', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246247', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246183', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246151', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246135', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246127', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246123', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246271', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246203', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246167', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246147', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246139', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_246131', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'syns_list': "['ACT-293987', 'NS-304', 'Selexipag']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'Recurrent thrombophlebitis', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.556 | Q34 | What are the names of the genes that are targeted by the drug Ropivacaine Hydrochloride in the treatment of pain? | In the context of pain, the drug Ropivacaine Hydrochloride targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%ropivacaine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%ropivacaine hydrochloride%" OR LOWER(syns_list) LIKE "%ropivacaine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_635739', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_635775', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_635865', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635787', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_635799', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_635805', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_635811', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_635841', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635829', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635835', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636201', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_635985', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_635997', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_663810', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663266', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635877', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_635883', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_635889', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_635895', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_635823', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635907', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_635919', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_635925', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_635931', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_635937', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_635943', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_635955', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_663198', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635751', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_635973', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_635979', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_663334', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635991', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_663130', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636003', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_663878', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635757', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_663742', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636027', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_636033', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_636039', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_636045', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_636051', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_635901', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_636063', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636069', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636075', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636081', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636087', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636093', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636099', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_636111', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636117', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636123', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636129', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636135', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636141', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636153', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_636159', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636165', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636171', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636177', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636183', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636189', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_636195', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_663606', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635961', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_635967', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_635781', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_635871', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_662790', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636021', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_635727', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_663538', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635853', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662994', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662858', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663470', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_635859', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663402', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663062', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663946', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_662926', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636015', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_635793', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_664014', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_663674', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636105', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_635913', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_635817', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_635769', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_635745', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_636057', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_636147', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_635949', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_635847', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_636009', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_635763', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_635733', 'drugName': 'Ropivacaine Hydrochloride', 'tradeNames_list': "['Narapin', 'Naropin', 'Ropivacaine hydrochloride']", 'syns_list': "['Ropivacaine hcl', 'Ropivacaine hydrochlorideRopivacaine hydrochloride hydrateRopivacaine hydrochloride monohydrate']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_663378', 'drugName': 'Bupivacaine', 'tradeNames_list': "['Anekain', 'Exparel', 'Marcaine', 'Posimir', 'Sensorcaine']", 'syns_list': "['Bucaine', 'Bupivacaine', 'Bupivacaine liposome', 'LIQ-865', 'LIQ865Liposomal bupivacaine', 'MarcaineRopivacaine hydrochloride impurity, bupivacaine-', 'SKY-0402', 'SKY0402Sensorcaine']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.950 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen Lysine in the treatment of Patent ductus arteriosus? | In the context of Patent ductus arteriosus, the drug Ibuprofen Lysine targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%patent ductus arteriosus%" OR LOWER(efo_term) LIKE "%patent ductus arteriosus%") AND (LOWER(drugName) LIKE "%ibuprofen lysine%" OR LOWER(tradeNames_list) LIKE "%ibuprofen lysine%" OR LOWER(syns_list) LIKE "%ibuprofen lysine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842285', 'drugName': 'Ibuprofen Lysine', 'tradeNames_list': "['Feminax express', 'Ibuprofen lysine', 'Neoprofen', 'Nurofen advanceNurofen max strgth mig pain', 'Nurofen migraine painNurofen tension headache']", 'syns_list': "['Arfen', 'Dolormin', 'Ibuprofen l-lysine', 'Ibuprofen lysinateIbuprofen lysine', 'Imbun', 'Lisiprofen', 'Saren', 'Solufenum', 'Soluphene']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842286', 'drugName': 'Ibuprofen Lysine', 'tradeNames_list': "['Feminax express', 'Ibuprofen lysine', 'Neoprofen', 'Nurofen advanceNurofen max strgth mig pain', 'Nurofen migraine painNurofen tension headache']", 'syns_list': "['Arfen', 'Dolormin', 'Ibuprofen l-lysine', 'Ibuprofen lysinateIbuprofen lysine', 'Imbun', 'Lisiprofen', 'Saren', 'Solufenum', 'Soluphene']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ductus Arteriosus, Patent', 'efo_term': 'Patent ductus arteriosus', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.741 | Q34 | What are the names of the genes that are targeted by the drug Morphine Sulfate in the treatment of pain? | In the context of pain, the drug Morphine Sulfate targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%morphine sulfate%" OR LOWER(tradeNames_list) LIKE "%morphine sulfate%" OR LOWER(syns_list) LIKE "%morphine sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763571', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763421', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763688', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763554', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763400', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763495', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763417', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763516', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763457', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763459', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763797', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763723', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763403', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763835', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763436', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763438', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763493', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763839', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763497', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763612', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763441', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763419', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763647', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763455', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763664', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763531', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763535', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763801', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763460', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763706', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763422', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763802', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763474', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763476', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763569', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763837', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763573', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763574', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763479', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763588', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763590', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763592', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763593', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763854', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763607', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763609', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763611', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763840', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763498', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763626', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763628', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763631', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763514', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763645', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763764', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763649', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763650', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763782', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763666', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763668', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763669', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763780', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763683', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763685', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763687', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763818', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763536', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763702', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763704', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763799', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763707', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763552', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763721', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763816', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763725', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763726', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763555', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763740', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763742', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763744', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763745', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763856', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763759', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763761', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763763', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763859', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763858', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763820', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763783', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763778', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763630', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763512', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763402', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763517', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763533', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chronic Pain', 'efo_term': 'Chronic pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763550', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763821', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763440', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763398', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain, Postoperative', 'efo_term': None, 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_763478', 'drugName': 'Morphine Sulfate', 'tradeNames_list': "['Arymo er', 'Astramorph pf', 'Avinza', 'Depodur', 'Duramorph', 'Duramorph pfDuromorph', 'Filnarine sr', 'Infumorph', 'Kadian', 'Moraxen', 'Morcap srMorphabond', 'Morphabond er', 'Morphgesic sr', 'Morphine sulfateMorphine sulfate (autoinjector)', 'Ms contin', 'Mst continus', 'OramorphOramorph sr', 'Oramorph udv', 'Rhotard', 'Sevredol', 'Srm-rhotard', 'Zomorph']", 'syns_list': "['Arymo', 'Astramorph', 'Dolcontin', 'Kapanol', 'Morcap', 'Morphine sulfateMorphine sulfate anhydrous', 'Morphine sulfate ciiMorphine sulfate hydrate', 'Morphine sulfate pentahydrateMorphine sulfate,anhydrous', 'Morphine sulphateMorphine sulphate anhydrous', 'Morphine sulphate pentahydrateMorphini sulfas', 'Moscontin', 'NSC-11441']", 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1341 | Q34 | What are the names of the genes that are targeted by the drug Capsaicin in the treatment of pain? | In the context of pain, the drug Capsaicin targets the gene transient receptor potential cation channel subfamily V member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%capsaicin%" OR LOWER(tradeNames_list) LIKE "%capsaicin%" OR LOWER(syns_list) LIKE "%capsaicin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993188', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993039', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993040', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993151', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993113', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993224', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993152', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993077', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993150', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993041', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993261', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993115', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993225', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993262', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993263', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993076', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993189', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993226', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993187', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Back Pain', 'efo_term': 'Back pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993078', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993114', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993096', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Facial Pain', 'efo_term': 'facial pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993170', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Facial Pain', 'efo_term': 'facial pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993171', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993059', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Facial Pain', 'efo_term': 'facial pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993097', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993207', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Facial Pain', 'efo_term': 'facial pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993208', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993245', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993022', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Facial Pain', 'efo_term': 'facial pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993023', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993133', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Facial Pain', 'efo_term': 'facial pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993134', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993060', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Myofascial Pain Syndromes', 'efo_term': 'myofascial pain syndrome', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993244', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Facial Pain', 'efo_term': 'facial pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.411 | Q34 | What are the names of the genes that are targeted by the drug Prednisolone Acetate in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Prednisolone Acetate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%prednisolone acetate%" OR LOWER(tradeNames_list) LIKE "%prednisolone acetate%" OR LOWER(syns_list) LIKE "%prednisolone acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243765', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243748', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243799', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243782', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'syns_list': "['NSC-10966', 'Prednisolone 21-acetate', 'Prednisolone AcetatePrednisolone acetate', 'Prednisoloni acetas']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1098 | Q34 | What are the names of the genes that are targeted by the drug Testosterone in the treatment of Klinefelter's syndrome? | In the context of Klinefelter's syndrome, the drug Testosterone targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%klinefelter's syndrome%" OR LOWER(efo_term) LIKE "%klinefelter's syndrome%") AND (LOWER(drugName) LIKE "%testosterone%" OR LOWER(tradeNames_list) LIKE "%testosterone%" OR LOWER(syns_list) LIKE "%testosterone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_922038', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922077', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922090', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922103', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922129', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922142', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922155', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922181', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922194', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922207', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922220', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922246', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922259', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922272', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922285', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922298', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922311', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922324', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922337', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922350', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922363', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922389', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922402', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922415', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922428', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922441', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922467', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922480', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922493', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922525', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922561', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922597', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922633', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922669', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922705', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922741', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922777', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922813', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922849', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922885', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922921', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922957', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922993', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923029', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923065', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923101', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923137', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923173', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923209', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923245', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923281', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923353', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923389', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923425', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923461', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923497', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923533', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923605', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923641', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923677', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923713', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923749', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923785', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923821', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923857', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923893', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923929', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923965', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924001', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924037', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924073', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924109', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924145', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924181', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924217', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924253', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924289', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924325', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_924361', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923317', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922376', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922168', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922064', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922012', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921986', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921973', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_923569', 'drugName': 'Testosterone', 'tradeNames_list': "['Androderm', 'Androgel', 'Androgel 1%', 'Andropatch', 'Axiron', 'FortestaIntrinsa', 'Natesto', 'Striant', 'Striant sr', 'Testim', 'Testim 1%Testoderm', 'Testoderm tts', 'Testogel', 'Testopatch', 'Testopel', 'TestoralTestosterone', 'Tostran', 'Vogelxo']", 'syns_list': "['Delatestryl', 'NSC-9700', 'TESTIM', 'Testosterone', 'Testosterone ciii']", 'yearOfFirstApproval': 1972, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922454', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922233', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922116', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922051', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_922025', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921999', 'drugName': 'Testosterone Undecanoate', 'tradeNames_list': "['Andriol', 'Aveed', 'Jatenzo', 'Kyzatrex', 'Nebido', 'RestandolRestandol testocap', 'Tlando', 'Undestor']", 'syns_list': "['Kyzatrex', 'MK-3033', 'ORG 538', 'ORG-538', 'TSX-011Testosterone 17.beta.-undecylate', 'Testosterone undecanoateTestosterone undecylate', 'Testosterone, undecanoate (ester)', 'Tlando']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Klinefelter Syndrome', 'efo_term': "Klinefelter's syndrome", 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1314 | Q34 | What are the names of the genes that are targeted by the drug Riociguat in the treatment of hypertension? | In the context of hypertension, the drug Riociguat targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%riociguat%" OR LOWER(tradeNames_list) LIKE "%riociguat%" OR LOWER(syns_list) LIKE "%riociguat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972925', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972936', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972937', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972938', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972948', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972949', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972950', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972960', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972961', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972962', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972963', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972973', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972974', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972975', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972984', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972985', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972986', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972987', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972996', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972997', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972998', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973008', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973009', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973010', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973011', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973020', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973022', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973023', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973032', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973033', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973034', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973035', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973044', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973045', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973046', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973047', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973056', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973057', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973058', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973059', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973068', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973069', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973070', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973071', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973080', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973081', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973082', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973083', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973092', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973093', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973094', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973104', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973105', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973106', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973107', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973116', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973117', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973119', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973128', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973129', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973130', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973131', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973140', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973141', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973142', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973143', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973152', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973153', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973154', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973155', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973164', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973165', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973166', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973167', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973176', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973177', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973178', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973179', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973188', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973189', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973190', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973191', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973200', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973201', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973202', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973203', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973095', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972999', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972951', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972927', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972915', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972913', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972912', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973118', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973021', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972972', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972939', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972926', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972924', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972914', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1448 | Q34 | What are the names of the genes that are targeted by the drug Tirzepatide in the treatment of type 2 diabetes mellitus? | In the context of type 2 diabetes mellitus, the drug Tirzepatide targets the gene glucagon like peptide 1 receptor and gastric inhibitory polypeptide receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%type 2 diabetes mellitus%" OR LOWER(efo_term) LIKE "%type 2 diabetes mellitus%") AND (LOWER(drugName) LIKE "%tirzepatide%" OR LOWER(tradeNames_list) LIKE "%tirzepatide%" OR LOWER(syns_list) LIKE "%tirzepatide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1045731', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045740', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045743', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045746', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045752', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045755', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045758', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045764', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045767', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045770', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045773', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045779', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045782', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045785', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045788', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045791', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045794', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045797', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045800', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045803', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045806', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045812', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045815', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045818', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045821', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045824', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045830', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045833', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045836', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045839', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045842', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045845', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045848', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045851', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045854', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045857', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045809', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045761', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045737', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045725', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045719', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045716', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045827', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GIPR', 'approvedName': 'gastric inhibitory polypeptide receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045776', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045749', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045734', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045728', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1045722', 'drugName': 'Tirzepatide', 'tradeNames_list': "['Mounjaro']", 'syns_list': "['LY-3298176', 'LY3298176', 'Ly3298176', 'Mounjaro', 'Tirzepatide']", 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GLP1R', 'approvedName': 'glucagon like peptide 1 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.816 | Q34 | What are the names of the genes that are targeted by the drug Indomethacin in the treatment of ankylosing spondylitis? | In the context of ankylosing spondylitis, the drug Indomethacin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ankylosing spondylitis%" OR LOWER(efo_term) LIKE "%ankylosing spondylitis%") AND (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_list) LIKE "%indomethacin%" OR LOWER(syns_list) LIKE "%indomethacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828373', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828475', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828509', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828543', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828441', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828305', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828237', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828203', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828577', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828407', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828339', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828271', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.542 | Q34 | What are the names of the genes that are targeted by the drug Azelastine Hydrochloride in the treatment of vasomotor rhinitis? | In the context of vasomotor rhinitis, the drug Azelastine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%vasomotor rhinitis%" OR LOWER(efo_term) LIKE "%vasomotor rhinitis%") AND (LOWER(drugName) LIKE "%azelastine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%azelastine hydrochloride%" OR LOWER(syns_list) LIKE "%azelastine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455910', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455934', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455942', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455950', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455894', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455878', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455870', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455926', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455918', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455902', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455886', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.623 | Q34 | What are the names of the genes that are targeted by the drug Tivozanib Hydrochloride in the treatment of renal cell carcinoma? | In the context of renal cell carcinoma, the drug Tivozanib Hydrochloride targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1, KIT proto-oncogene, receptor tyrosine kinase, fms related receptor tyrosine kinase 4 and platelet derived growth factor receptor beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal cell carcinoma%" OR LOWER(efo_term) LIKE "%renal cell carcinoma%") AND (LOWER(drugName) LIKE "%tivozanib hydrochloride%" OR LOWER(tradeNames_list) LIKE "%tivozanib hydrochloride%" OR LOWER(syns_list) LIKE "%tivozanib hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_682894', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_682903', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_682906', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_682909', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_682915', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_682918', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_682921', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_682927', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_682930', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_682933', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_682936', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_682900', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_682888', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_682882', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_682879', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_682924', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_682912', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_682897', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_682891', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_682885', 'drugName': 'Tivozanib Hydrochloride', 'tradeNames_list': "['Fotivda']", 'syns_list': "['AV-951', 'Tivozanib hydrochloride', 'Tivozanib hydrochloride monohydrate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.184 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of arthritis? | In the context of arthritis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%arthritis%" OR LOWER(efo_term) LIKE "%arthritis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217679', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217848', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217852', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217858', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218050', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218052', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218056', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218066', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218095', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218258', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218260', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218268', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218274', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218303', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218466', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218468', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218472', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218476', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218482', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218511', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218674', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218680', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218684', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218690', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218719', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218882', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218888', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218892', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218898', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218927', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219090', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219092', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219096', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219100', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219106', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219135', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219298', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219300', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219304', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219308', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219314', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219343', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219506', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219508', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219512', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219516', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219522', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219551', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219714', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219716', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219720', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219730', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219759', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219922', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219924', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219928', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219932', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219967', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220130', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220132', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220136', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220140', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220146', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220175', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220338', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220340', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220344', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220348', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220354', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220383', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220546', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220548', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220552', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220556', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220562', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220591', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220754', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220756', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220760', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220764', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220770', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220799', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219724', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218676', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218060', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217844', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217644', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217636', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217634', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219938', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218884', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218264', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217887', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217842', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217650', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217640', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Psoriatic', 'efo_term': 'psoriatic arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.863 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of coronary artery disease? | In the context of coronary artery disease, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%coronary artery disease%" OR LOWER(efo_term) LIKE "%coronary artery disease%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834433', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834904', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835061', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835218', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835532', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835689', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835846', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836003', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834747', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834119', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833805', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833648', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835375', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834590', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834276', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833962', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.172 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of polymyositis? | In the context of polymyositis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%polymyositis%" OR LOWER(efo_term) LIKE "%polymyositis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218678', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219302', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219510', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219718', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220134', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220342', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220550', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220758', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219094', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218262', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217846', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217638', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219926', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218886', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218470', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218054', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polymyositis', 'efo_term': 'polymyositis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.294 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of leukemia? | In the context of leukemia, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%leukemia%" OR LOWER(efo_term) LIKE "%leukemia%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_231739', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229744', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230884', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227749', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228034', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227179', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229174', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227464', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232024', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231454', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226609', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226894', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230314', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228319', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232309', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230599', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230029', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226324', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229459', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228604', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231169', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228889', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia', 'efo_term': 'leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226783', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227139', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226308', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227643', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Acute', 'efo_term': 'acute myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226808', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloblastic leukemia without maturation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226219', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226785', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227703', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226787', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226498', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227704', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'precursor T-cell lymphoblastic leukemia-lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226784', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Erythroblastic, Acute', 'efo_term': 'acute erythroleukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227644', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226493', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226208', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227662', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Megakaryoblastic, Acute', 'efo_term': 'acute megakaryoblastic leukaemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227445', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'acute leukemia of ambiguous lineage', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227633', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226778', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227358', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Acute', 'efo_term': 'acute myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226503', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Acute', 'efo_term': 'acute myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226278', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226786', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Monocytic, Acute', 'efo_term': 'acute monocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227378', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloblastic leukemia without maturation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227640', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227641', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Monocytic, Acute', 'efo_term': 'acute monocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226788', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Acute', 'efo_term': 'acute myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226789', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226807', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Megakaryoblastic, Acute', 'efo_term': 'acute megakaryoblastic leukaemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226848', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226590', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'acute leukemia of ambiguous lineage', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227348', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226570', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226569', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226305', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'acute leukemia of ambiguous lineage', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227163', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227663', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloblastic leukemia without maturation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227140', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227419', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'precursor T-cell lymphoblastic leukemia-lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227134', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'precursor T-cell lymphoblastic leukemia-lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227377', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Megakaryoblastic, Acute', 'efo_term': 'acute megakaryoblastic leukaemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227418', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226593', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227074', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226216', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Monocytic, Acute', 'efo_term': 'acute monocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227072', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227073', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Acute', 'efo_term': 'acute myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227092', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Megakaryoblastic, Acute', 'efo_term': 'acute megakaryoblastic leukaemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227093', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloblastic leukemia without maturation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227133', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227424', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227070', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226217', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227448', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'T-lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227160', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'acute leukemia of ambiguous lineage', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227063', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'B-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226522', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Megakaryoblastic, Acute', 'efo_term': 'acute megakaryoblastic leukaemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226284', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227069', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Erythroblastic, Acute', 'efo_term': 'acute erythroleukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227068', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227709', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227355', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226523', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloblastic leukemia without maturation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226215', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227638', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Biphenotypic, Acute', 'efo_term': 'T-cell acute lymphoblastic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227356', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Monocytic, Acute', 'efo_term': 'acute monocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226504', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Promyelocytic, Acute', 'efo_term': 'acute promyelocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226279', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'precursor T-cell lymphoblastic leukemia-lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227357', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226214', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Erythroblastic, Acute', 'efo_term': 'acute erythroleukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226285', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226563', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227071', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Monocytic, Acute', 'efo_term': 'acute monocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226564', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Precursor T-Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'precursor T-cell lymphoblastic leukemia-lymphoma', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227642', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myeloid, Acute', 'efo_term': 'acute myeloid leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227639', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Erythroblastic, Acute', 'efo_term': 'acute erythroleukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226218', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Acute', 'efo_term': 'acute myelomonocytic leukemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226237', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Leukemia, Megakaryoblastic, Acute', 'efo_term': 'acute megakaryoblastic leukaemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1525 | Q34 | What are the names of the genes that are targeted by the drug Risdiplam in the treatment of Atrophy? | In the context of Atrophy, the drug Risdiplam targets the gene survival of motor neuron 2, centromeric. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atrophy%" OR LOWER(efo_term) LIKE "%atrophy%") AND (LOWER(drugName) LIKE "%risdiplam%" OR LOWER(tradeNames_list) LIKE "%risdiplam%" OR LOWER(syns_list) LIKE "%risdiplam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072736', 'drugName': 'Risdiplam', 'tradeNames_list': "['Evrysdi']", 'syns_list': "['RG-7916', 'RG7916', 'RO-7034067', 'RO7034067', 'Risdiplam']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrophy', 'efo_term': 'Atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072735', 'drugName': 'Risdiplam', 'tradeNames_list': "['Evrysdi']", 'syns_list': "['RG-7916', 'RG7916', 'RO-7034067', 'RO7034067', 'Risdiplam']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072738', 'drugName': 'Risdiplam', 'tradeNames_list': "['Evrysdi']", 'syns_list': "['RG-7916', 'RG7916', 'RO-7034067', 'RO7034067', 'Risdiplam']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Atrophy', 'efo_term': 'Atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}, {'UUID': 'DrugTargetsIndication121923_text_1072737', 'drugName': 'Risdiplam', 'tradeNames_list': "['Evrysdi']", 'syns_list': "['RG-7916', 'RG7916', 'RO-7034067', 'RO7034067', 'Risdiplam']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Atrophy, Spinal', 'efo_term': 'spinal muscular atrophy', 'approvedSymbol': 'SMN2', 'approvedName': 'survival of motor neuron 2, centromeric'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1797 | Q34 | What are the names of the genes that are targeted by the drug Nizatidine in the treatment of duodenal ulcer? | In the context of duodenal ulcer, the drug Nizatidine targets the gene histamine receptor H2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%duodenal ulcer%" OR LOWER(efo_term) LIKE "%duodenal ulcer%") AND (LOWER(drugName) LIKE "%nizatidine%" OR LOWER(tradeNames_list) LIKE "%nizatidine%" OR LOWER(syns_list) LIKE "%nizatidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100311', 'drugName': 'Nizatidine', 'tradeNames_list': "['Axid', 'Axid ar', 'Nizatidine', 'Zinga 150', 'Zinga 300']", 'syns_list': "['Acinon', 'LY 139037', 'LY-139037', 'NSC-759289', 'Nizatidine']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Duodenal Ulcer', 'efo_term': 'duodenal ulcer', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.302 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of pneumonia? | In the context of pneumonia, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pneumonia%" OR LOWER(efo_term) LIKE "%pneumonia%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_228042', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230892', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226349', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227187', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226634', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227204', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230624', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229467', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227489', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228629', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232049', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230322', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228327', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231747', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231462', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228612', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228344', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226617', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230607', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230909', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226919', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229199', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229484', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227757', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232317', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227472', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231479', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230037', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228914', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228059', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228897', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230339', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227774', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232032', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232334', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229182', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226902', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231177', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231764', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230054', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229769', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229752', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pneumonia', 'efo_term': 'pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231194', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Eosinophilia', 'efo_term': 'eosinophilic pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232248', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227973', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229683', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229968', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230253', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228258', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230538', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226833', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227403', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228543', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227118', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230823', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231108', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231393', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228828', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229398', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231678', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226263', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226548', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227688', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229113', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231963', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Pneumonia, Viral', 'efo_term': 'viral pneumonia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1859 | Q34 | What are the names of the genes that are targeted by the drug Pitavastatin Calcium in the treatment of Abnormal circulating lipid concentration? | In the context of Abnormal circulating lipid concentration, the drug Pitavastatin Calcium targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%abnormal circulating lipid concentration%" OR LOWER(efo_term) LIKE "%abnormal circulating lipid concentration%") AND (LOWER(drugName) LIKE "%pitavastatin calcium%" OR LOWER(tradeNames_list) LIKE "%pitavastatin calcium%" OR LOWER(syns_list) LIKE "%pitavastatin calcium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104277', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104289', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104293', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104297', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104285', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104269', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104261', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104257', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104301', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104281', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104273', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104265', 'drugName': 'Pitavastatin Calcium', 'tradeNames_list': "['Livalo', 'Pitavastatin calcium']", 'syns_list': "['Itavastatin calcium', 'NK-104', 'Pitavastatin CalciumPitavastatin calcium', 'Pitavastatin calcium salt']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dyslipidemias', 'efo_term': 'Abnormal circulating lipid concentration', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.538 | Q34 | What are the names of the genes that are targeted by the drug Azelastine Hydrochloride in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Azelastine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%azelastine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%azelastine hydrochloride%" OR LOWER(syns_list) LIKE "%azelastine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455905', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455929', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455937', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455945', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455889', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455873', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455865', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455921', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455913', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455897', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455881', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'syns_list': "['A-5610', 'Azelastine hcl', 'Azelastine hydrochloride', 'E-0659', 'W-2979M']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1637 | Q34 | What are the names of the genes that are targeted by the drug Ubrogepant in the treatment of migraine disorder? | In the context of migraine disorder, the drug Ubrogepant targets the gene calcitonin receptor like receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%ubrogepant%" OR LOWER(tradeNames_list) LIKE "%ubrogepant%" OR LOWER(syns_list) LIKE "%ubrogepant%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094036', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094039', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094040', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094038', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094032', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094031', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094034', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094037', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094035', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1094033', 'drugName': 'Ubrogepant', 'tradeNames_list': "['Ubrelvy']", 'syns_list': "['MK-1602', 'Ubrogepant', 'Ubrogepant anhydrous']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'CALCRL', 'approvedName': 'calcitonin receptor like receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1246 | Q34 | What are the names of the genes that are targeted by the drug Dutetrabenazine in the treatment of chorea? | In the context of chorea, the drug Dutetrabenazine targets the gene solute carrier family 18 member A2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chorea%" OR LOWER(efo_term) LIKE "%chorea%") AND (LOWER(drugName) LIKE "%dutetrabenazine%" OR LOWER(tradeNames_list) LIKE "%dutetrabenazine%" OR LOWER(syns_list) LIKE "%dutetrabenazine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938616', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938634', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938640', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938646', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938658', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938664', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938670', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938682', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938688', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938694', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938700', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938712', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938718', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938724', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938730', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938736', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938742', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938748', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938754', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938760', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938766', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938778', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938784', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938790', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938796', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938802', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938814', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938820', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938826', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938832', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938838', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938844', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938850', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938856', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938862', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938868', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938874', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938880', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938886', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938892', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938898', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938904', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938910', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938916', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938922', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938772', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938676', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938628', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938604', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938592', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938586', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938808', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938706', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938652', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938622', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938610', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}, {'UUID': 'DrugTargetsIndication121923_text_938598', 'drugName': 'Dutetrabenazine', 'tradeNames_list': "['Austedo']", 'syns_list': "['Deutetrabenazine', 'Dutetrabenazine', 'SD-809']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorea', 'efo_term': 'chorea', 'approvedSymbol': 'SLC18A2', 'approvedName': 'solute carrier family 18 member A2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1912 | Q34 | What are the names of the genes that are targeted by the drug Tafluprost in the treatment of open-angle glaucoma? | In the context of open-angle glaucoma, the drug Tafluprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%open-angle glaucoma%" OR LOWER(efo_term) LIKE "%open-angle glaucoma%") AND (LOWER(drugName) LIKE "%tafluprost%" OR LOWER(tradeNames_list) LIKE "%tafluprost%" OR LOWER(syns_list) LIKE "%tafluprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149434', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149437', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149440', 'drugName': 'Tafluprost', 'tradeNames_list': "['Saflutan', 'Zioptan']", 'syns_list': "['AFP-168', 'MK-2452', 'Tafluprost']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma, Open-Angle', 'efo_term': 'open-angle glaucoma', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.274 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Furoate in the treatment of Nasal congestion? | In the context of Nasal congestion, the drug Fluticasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal congestion%" OR LOWER(efo_term) LIKE "%nasal congestion%") AND (LOWER(drugName) LIKE "%fluticasone furoate%" OR LOWER(tradeNames_list) LIKE "%fluticasone furoate%" OR LOWER(syns_list) LIKE "%fluticasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225657', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225684', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225693', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225702', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225720', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225729', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225738', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225756', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225765', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225774', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225783', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225801', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225810', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225819', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225828', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225837', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225846', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225855', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225864', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225873', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225882', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225900', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225909', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225918', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225927', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225936', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225954', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225963', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225972', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225981', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225990', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225999', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226008', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226017', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226026', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226035', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226044', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226053', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226062', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226071', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226080', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226089', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226098', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225891', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225747', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225675', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225639', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225621', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225612', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225945', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225792', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225711', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225666', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225648', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225630', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Obstruction', 'efo_term': 'Nasal congestion', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1532 | Q34 | What are the names of the genes that are targeted by the drug Fosaprepitant Dimeglumine in the treatment of Nausea and vomiting? | In the context of Nausea and vomiting, the drug Fosaprepitant Dimeglumine targets the gene tachykinin receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nausea and vomiting%" OR LOWER(efo_term) LIKE "%nausea and vomiting%") AND (LOWER(drugName) LIKE "%fosaprepitant dimeglumine%" OR LOWER(tradeNames_list) LIKE "%fosaprepitant dimeglumine%" OR LOWER(syns_list) LIKE "%fosaprepitant dimeglumine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1073161', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073166', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073168', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073170', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073173', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073175', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073176', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073180', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073181', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073183', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073185', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073178', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073165', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073158', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073155', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073153', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073186', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073171', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073163', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073160', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073156', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1342 | Q34 | What are the names of the genes that are targeted by the drug Capsaicin in the treatment of neuropathic pain? | In the context of neuropathic pain, the drug Capsaicin targets the gene transient receptor potential cation channel subfamily V member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neuropathic pain%" OR LOWER(efo_term) LIKE "%neuropathic pain%") AND (LOWER(drugName) LIKE "%capsaicin%" OR LOWER(tradeNames_list) LIKE "%capsaicin%" OR LOWER(syns_list) LIKE "%capsaicin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993226', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993152', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993078', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993041', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993263', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993189', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993115', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.870 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of toothache? | In the context of toothache, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%toothache%" OR LOWER(efo_term) LIKE "%toothache%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834440', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834911', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835068', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835225', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835539', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835696', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835853', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836010', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834754', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834126', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833812', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833655', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835382', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834597', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834283', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833969', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Toothache', 'efo_term': 'toothache', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.425 | Q34 | What are the names of the genes that are targeted by the drug Treprostinil in the treatment of pulmonary arterial hypertension? | In the context of pulmonary arterial hypertension, the drug Treprostinil targets the gene prostaglandin I2 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%treprostinil%" OR LOWER(tradeNames_list) LIKE "%treprostinil%" OR LOWER(syns_list) LIKE "%treprostinil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_244484', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244517', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244518', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244534', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244551', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244552', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244568', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244585', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244586', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244602', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244603', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244620', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244636', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244637', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244653', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244654', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244670', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244671', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244687', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244688', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244704', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244721', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244722', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244738', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244739', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244755', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244772', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244773', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244789', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244790', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244806', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244807', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244823', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244824', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244840', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244841', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244857', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244858', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244874', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244875', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244891', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244892', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244908', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244909', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244925', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244926', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244942', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244943', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244959', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244960', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244976', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244993', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244994', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245010', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245011', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245027', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245028', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245045', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245061', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245062', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245078', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245079', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245095', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245096', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245112', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245113', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245129', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245130', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245146', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245147', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245163', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245164', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245180', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245181', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245197', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245198', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245214', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245215', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245231', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245232', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245248', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245249', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245265', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245266', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245282', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245283', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244977', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244705', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244569', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244501', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244467', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244450', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244449', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_245044', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244756', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244619', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244535', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Arterial Hypertension', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244500', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244483', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_244466', 'drugName': 'Treprostinil', 'tradeNames_list': "['Remodulin', 'Tyvaso', 'Tyvaso dpi']", 'syns_list': "['15-AU-81', '15AU81', 'L-606', 'LRX -15', 'LRX-15', 'Rumodolin', 'TreprostinilTresprostinil', 'UT-15', 'Uniprost']", 'yearOfFirstApproval': 2002, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.373 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone in the treatment of Crohn's disease? | In the context of Crohn's disease, the drug Hydrocortisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%crohn's disease%" OR LOWER(efo_term) LIKE "%crohn's disease%") AND (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone%" OR LOWER(syns_list) LIKE "%hydrocortisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218668', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219292', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219500', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219708', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220124', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220332', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220540', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240812', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240894', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240976', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241058', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241222', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241304', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241386', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241468', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241550', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241632', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241714', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241796', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241878', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220748', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219084', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218252', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217836', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217628', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241140', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219916', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218876', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218460', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218044', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Crohn Disease', 'efo_term': "Crohn's disease", 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1789 | Q34 | What are the names of the genes that are targeted by the drug Dantrolene Sodium in the treatment of Fever? | In the context of Fever, the drug Dantrolene Sodium targets the gene ryanodine receptor 3 and ryanodine receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fever%" OR LOWER(efo_term) LIKE "%fever%") AND (LOWER(drugName) LIKE "%dantrolene sodium%" OR LOWER(tradeNames_list) LIKE "%dantrolene sodium%" OR LOWER(syns_list) LIKE "%dantrolene sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100264', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100291', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100300', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100282', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100228', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100219', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100246', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100273', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100255', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100237', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperthermia', 'efo_term': 'Fever', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.980 | Q34 | What are the names of the genes that are targeted by the drug Abemaciclib in the treatment of breast carcinoma? | In the context of breast carcinoma, the drug Abemaciclib targets the gene cyclin dependent kinase 4 and cyclin dependent kinase 6. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast carcinoma%" OR LOWER(efo_term) LIKE "%breast carcinoma%") AND (LOWER(drugName) LIKE "%abemaciclib%" OR LOWER(tradeNames_list) LIKE "%abemaciclib%" OR LOWER(syns_list) LIKE "%abemaciclib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_849246', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849348', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849195', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850164', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850368', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849297', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850266', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850827', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849654', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850572', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849144', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850623', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849552', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849603', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851184', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850317', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849399', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849960', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849093', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850470', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850980', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850725', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850878', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850113', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850062', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850776', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850011', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849756', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849501', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851082', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849909', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850215', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849858', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850929', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851133', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850674', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849705', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851235', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850419', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849450', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849807', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851286', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851031', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850521', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850204', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850255', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850663', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849388', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849694', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850306', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850357', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849745', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850408', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850459', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849133', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849235', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849796', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850510', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850561', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849643', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849082', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849286', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849490', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849898', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850765', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849949', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850816', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849439', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849541', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850000', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850918', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850867', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850969', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850051', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851020', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851071', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850714', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849337', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849592', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850102', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851122', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849184', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851173', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850153', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851224', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851275', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850612', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849847', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms, Male', 'efo_term': 'male breast carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1753 | Q34 | What are the names of the genes that are targeted by the drug Omeprazole in the treatment of infection? | In the context of infection, the drug Omeprazole targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%infection%" OR LOWER(efo_term) LIKE "%infection%") AND (LOWER(drugName) LIKE "%omeprazole%" OR LOWER(tradeNames_list) LIKE "%omeprazole%" OR LOWER(syns_list) LIKE "%omeprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097966', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098246', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098176', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098316', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098036', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098106', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098237', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098307', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098097', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097957', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097868', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098027', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098167', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097856', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097892', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097880', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Helicobacter Infections', 'efo_term': 'Helicobacter pylori infectious disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098254', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098057', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C', 'efo_term': 'hepatitis C virus infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098127', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C', 'efo_term': 'hepatitis C virus infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098114', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097904', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098125', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097921', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis B, Chronic', 'efo_term': 'chronic hepatitis B virus infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097989', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098129', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097915', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097974', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098055', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098059', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098275', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Clostridium Infections', 'efo_term': 'clostridium difficile infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098269', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098267', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C', 'efo_term': 'hepatitis C virus infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097995', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Clostridium Infections', 'efo_term': 'clostridium difficile infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098061', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis B, Chronic', 'efo_term': 'chronic hepatitis B virus infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098065', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Clostridium Infections', 'efo_term': 'clostridium difficile infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098265', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098271', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis B, Chronic', 'efo_term': 'chronic hepatitis B virus infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098184', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098195', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098135', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Clostridium Infections', 'efo_term': 'clostridium difficile infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097991', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis B, Chronic', 'efo_term': 'chronic hepatitis B virus infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098131', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis B, Chronic', 'efo_term': 'chronic hepatitis B virus infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098197', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C', 'efo_term': 'hepatitis C virus infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098201', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis B, Chronic', 'efo_term': 'chronic hepatitis B virus infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097919', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097925', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Clostridium Infections', 'efo_term': 'clostridium difficile infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098044', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098199', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C, Chronic', 'efo_term': 'chronic hepatitis C virus infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098205', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Clostridium Infections', 'efo_term': 'clostridium difficile infection', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097917', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C', 'efo_term': 'hepatitis C virus infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097985', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097987', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'syns_list': "['H 168/68', 'H-168/68', 'NSC-751450', 'NSC-759192', 'Omeprazole']", 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Hepatitis C', 'efo_term': 'hepatitis C virus infection', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.698 | Q34 | What are the names of the genes that are targeted by the drug Apixaban in the treatment of pulmonary embolism? | In the context of pulmonary embolism, the drug Apixaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary embolism%" OR LOWER(efo_term) LIKE "%pulmonary embolism%") AND (LOWER(drugName) LIKE "%apixaban%" OR LOWER(tradeNames_list) LIKE "%apixaban%" OR LOWER(syns_list) LIKE "%apixaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710508', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710595', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710624', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710653', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710711', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710740', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710769', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710566', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710450', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710392', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710363', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710682', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710537', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710479', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710421', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.706 | Q34 | What are the names of the genes that are targeted by the drug Umbralisib Tosylate in the treatment of marginal zone B-cell lymphoma? | In the context of marginal zone B-cell lymphoma, the drug Umbralisib Tosylate targets the gene ABL proto-oncogene 1, non-receptor tyrosine kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta and casein kinase 1 epsilon. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%marginal zone b-cell lymphoma%" OR LOWER(efo_term) LIKE "%marginal zone b-cell lymphoma%") AND (LOWER(drugName) LIKE "%umbralisib tosylate%" OR LOWER(tradeNames_list) LIKE "%umbralisib tosylate%" OR LOWER(syns_list) LIKE "%umbralisib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_744696', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744741', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744756', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744771', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744801', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744816', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744831', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744861', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744876', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744891', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744906', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744936', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744951', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744966', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744981', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744996', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_745011', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_745026', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_745041', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_745056', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_745071', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745101', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745116', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745131', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745146', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745161', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745191', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745206', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745221', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745236', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745251', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745266', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745281', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_745086', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_744846', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744726', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744666', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744636', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744621', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745176', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'CSNK1E', 'approvedName': 'casein kinase 1 epsilon'}, {'UUID': 'DrugTargetsIndication121923_text_744921', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta'}, {'UUID': 'DrugTargetsIndication121923_text_744786', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744711', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744681', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_744651', 'drugName': 'Umbralisib Tosylate', 'tradeNames_list': "['Ukoniq']", 'syns_list': "['RP-5307', 'TGR-1202', 'TGR-1202 (4-METHYLBENZENESULFONATE)', 'Tgr-1202Umbralisib tosylate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, B-Cell, Marginal Zone', 'efo_term': 'marginal zone B-cell lymphoma', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1011 | Q34 | What are the names of the genes that are targeted by the drug Ipratropium Bromide in the treatment of emphysema? | In the context of emphysema, the drug Ipratropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%emphysema%" OR LOWER(efo_term) LIKE "%emphysema%") AND (LOWER(drugName) LIKE "%ipratropium bromide%" OR LOWER(tradeNames_list) LIKE "%ipratropium bromide%" OR LOWER(syns_list) LIKE "%ipratropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857477', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'syns_list': "['Ipratropium bromide', 'Ipratropium bromide anhydrousIpratropium bromide hydrate', 'Ipratropium bromide monohydrateNSC-759613', 'SCH 1000-BR-MONOHYDRATE', 'SCH-1000-BR-']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Emphysema', 'efo_term': 'emphysema', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1352 | Q34 | What are the names of the genes that are targeted by the drug Tranexamic Acid in the treatment of hemophilia A? | In the context of hemophilia A, the drug Tranexamic Acid targets the gene plasminogen. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemophilia a%" OR LOWER(efo_term) LIKE "%hemophilia a%") AND (LOWER(drugName) LIKE "%tranexamic acid%" OR LOWER(tradeNames_list) LIKE "%tranexamic acid%" OR LOWER(syns_list) LIKE "%tranexamic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993619', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993735', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993503', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993387', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993329', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993677', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993561', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}, {'UUID': 'DrugTargetsIndication121923_text_993445', 'drugName': 'Tranexamic Acid', 'tradeNames_list': "['Cyklo-f heavy period relief', 'Cyklokapron', 'Exacyl', 'LystedaMenstralite', 'Tranexamic acid']", 'syns_list': "['Amcha', 'CL 65336', 'CL-65336', 'Cyclo-f', 'Cyclocapron', 'CyclokapronEspercil', 'Femstrual', 'Haematrix', 'LB-1148', 'LB1148', 'NSC-291305RP-18429', 'Rikavarin', 'TRANS AMCHA', 'TRANS-AMCHA', 'Tranexamic acidTrans AMCHA', 'Transamin']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemophilia A', 'efo_term': 'hemophilia A', 'approvedSymbol': 'PLG', 'approvedName': 'plasminogen'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.177 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of nephrotic syndrome? | In the context of nephrotic syndrome, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nephrotic syndrome%" OR LOWER(efo_term) LIKE "%nephrotic syndrome%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218683', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219307', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219515', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219723', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220139', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220347', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220555', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220763', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219099', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218267', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217851', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217643', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219931', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218891', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218475', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218059', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1805 | Q34 | What are the names of the genes that are targeted by the drug Famotidine in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Famotidine targets the gene histamine receptor H2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%famotidine%" OR LOWER(tradeNames_list) LIKE "%famotidine%" OR LOWER(syns_list) LIKE "%famotidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100339', 'drugName': 'Famotidine', 'tradeNames_list': "['Famotidine', 'Famotidine preservative freeFamotidine preservative free (pharmacy bulk)', 'Fluxid', 'PepcidPepcid ac', 'Pepcid preservative free', 'Pepcid rpd']", 'syns_list': "['Amfamox', 'Fadul', 'Famodil', 'Famosan', 'Famotidine', 'Famoxal', 'GanorGastridin', 'Gastropen', 'L 643341', 'Lecedil', 'MK-208', 'Motiax', 'MucloxNSC-757810', 'Pepcidac', 'Pepdine', 'Pepdul', 'YM-11170']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1410 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of ornithosis? | In the context of ornithosis, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ornithosis%" OR LOWER(efo_term) LIKE "%ornithosis%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1038224', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038449', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038524', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038599', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038749', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038824', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038899', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039049', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039124', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039199', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039274', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039424', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039499', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039574', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039649', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039724', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039799', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039874', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039949', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040024', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040099', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040249', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040324', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040399', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040474', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040549', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040699', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040774', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040849', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040924', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040999', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041074', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040174', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038974', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038374', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038074', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037924', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037849', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040624', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039349', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038674', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038299', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038149', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037999', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psittacosis', 'efo_term': 'ornithosis', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.921 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of spondylitis? | In the context of spondylitis, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spondylitis%" OR LOWER(efo_term) LIKE "%spondylitis%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838133', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838184', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838201', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838218', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838252', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838269', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838286', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838335', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838346', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838376', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838387', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838428', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838458', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838469', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838499', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838510', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838540', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838551', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838581', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838592', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838622', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838663', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838674', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838704', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838715', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838745', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838786', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838797', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838827', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838838', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838868', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838879', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838909', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838920', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838950', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838961', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838991', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839002', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839032', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839043', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839073', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839084', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839114', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839125', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839155', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839166', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839196', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839207', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839237', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839248', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839278', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839319', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839330', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839360', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839371', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839401', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839412', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839453', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839483', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839494', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839524', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839535', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839565', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839576', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839606', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839617', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839647', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839658', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839688', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839699', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839289', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838633', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838303', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838167', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838099', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838065', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838048', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839442', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838756', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838417', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838235', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838150', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838116', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838082', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.749 | Q34 | What are the names of the genes that are targeted by the drug Methylnaltrexone Bromide in the treatment of Constipation? | In the context of Constipation, the drug Methylnaltrexone Bromide targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%constipation%" OR LOWER(efo_term) LIKE "%constipation%") AND (LOWER(drugName) LIKE "%methylnaltrexone bromide%" OR LOWER(tradeNames_list) LIKE "%methylnaltrexone bromide%" OR LOWER(syns_list) LIKE "%methylnaltrexone bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_766657', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766666', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766669', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766672', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766678', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766681', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766684', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766690', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766693', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766696', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766699', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766705', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766708', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766711', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766714', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766717', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766720', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766723', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766726', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766729', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766732', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766738', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766735', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766687', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766663', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766651', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766642', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766645', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766702', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766675', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766660', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766654', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_766648', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'syns_list': "['MRZ 2663BR', 'MRZ-2663BR', 'Methylnaltrexone bromide', 'Moa-728N-methylnaltrexone bromide', 'Naltrexone methobromideNaltrexone methylbromide']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.336 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of mycosis fungoides? | In the context of mycosis fungoides, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%mycosis fungoides%" OR LOWER(efo_term) LIKE "%mycosis fungoides%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227792', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228647', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228932', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229217', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229787', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230072', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230357', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230927', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231212', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231497', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231782', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232352', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230642', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228362', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227222', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226652', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226367', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232067', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229502', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228077', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227507', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226937', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mycosis Fungoides', 'efo_term': 'mycosis fungoides', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.887 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac in the treatment of keratosis? | In the context of keratosis, the drug Diclofenac targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%keratosis%" OR LOWER(efo_term) LIKE "%keratosis%") AND (LOWER(drugName) LIKE "%diclofenac%" OR LOWER(tradeNames_list) LIKE "%diclofenac%" OR LOWER(syns_list) LIKE "%diclofenac%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_837193', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837398', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837908', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837493', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837373', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837668', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837073', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837008', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837788', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837313', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837938', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838003', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837553', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837578', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837368', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837793', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837458', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837613', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837968', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837848', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837103', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837163', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837728', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837223', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837818', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837283', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837343', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837998', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837403', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837133', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837013', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838033', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837523', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837518', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837583', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837428', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837638', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838028', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836983', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836978', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837253', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837463', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837548', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837913', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837038', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837608', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837068', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837853', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837098', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837338', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837128', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837158', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837698', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837188', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837758', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837218', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837733', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837878', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837278', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837643', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837883', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837763', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837703', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837673', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837043', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837943', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837308', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837973', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837248', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837823', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_837433', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_837488', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'syns_list': "['Arthrotec', 'Cataflam', 'Diclofenac', 'Diclofenac acidDiclofenac free acid', 'LAS-41007', 'LAS41007', 'Las41007', 'SolarazeVoltaren', 'Voltaren-XR']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836782', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836206', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836404', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836800', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836818', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836836', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836854', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836062', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836224', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836440', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836872', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836116', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836890', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836458', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836908', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836926', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836422', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836242', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836476', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836944', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836494', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836134', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836260', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836512', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836530', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836278', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836548', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836566', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Keratosis, Actinic', 'efo_term': 'actinic keratosis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1369 | Q34 | What are the names of the genes that are targeted by the drug Zanubrutinib in the treatment of cancer? | In the context of cancer, the drug Zanubrutinib targets the gene Bruton tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%zanubrutinib%" OR LOWER(tradeNames_list) LIKE "%zanubrutinib%" OR LOWER(syns_list) LIKE "%zanubrutinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1025173', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025224', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025241', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025207', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025105', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025088', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025139', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025190', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025156', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_1025122', 'drugName': 'Zanubrutinib', 'tradeNames_list': "['Brukinsa']", 'syns_list': "['BGB-3111', 'Bgb-3111', 'Zanubrutinib']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1154 | Q34 | What are the names of the genes that are targeted by the drug Trametinib in the treatment of cholangiocarcinoma? | Trametinib has not been approved by the FDA as a treatment for cholangiocarcinoma, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target names are mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cholangiocarcinoma%" OR LOWER(efo_term) LIKE "%cholangiocarcinoma%") AND (LOWER(drugName) LIKE "%trametinib%" OR LOWER(tradeNames_list) LIKE "%trametinib%" OR LOWER(syns_list) LIKE "%trametinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_928702', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928822', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928862', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928902', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928982', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929022', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929062', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929142', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929182', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929222', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929262', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929342', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929382', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929422', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929462', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929502', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929542', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929582', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929622', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929662', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929702', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929782', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929822', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929862', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929902', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929942', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930022', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930062', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930102', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930142', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930182', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930222', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930262', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930302', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930342', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930382', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930422', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930462', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930502', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930542', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930582', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930622', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_930662', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930702', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930742', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930782', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930822', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930862', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930902', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930942', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_930982', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931062', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931102', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931142', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931182', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931222', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931262', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931342', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931382', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931422', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931462', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931502', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931542', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931582', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931622', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931662', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931702', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931742', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931782', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931822', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931862', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931902', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931942', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931982', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932022', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932062', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932102', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932142', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932182', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932222', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932262', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932302', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932342', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932382', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932422', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_932462', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_931022', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929742', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929102', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928782', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928622', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928542', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928502', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_931302', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_929982', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_929302', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928942', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928742', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928662', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_928582', 'drugName': 'Trametinib', 'tradeNames_list': "['Mekinist']", 'syns_list': "['GSK-1120212', 'GSK1120212', 'JTP 74057', 'JTP-74057', 'TMT-212', 'TMT212Tmt212', 'Trametinib']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1041 | Q34 | What are the names of the genes that are targeted by the drug Ziconotide in the treatment of Fever? | In the context of Fever, the drug Ziconotide targets the gene calcium voltage-gated channel subunit alpha1 B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fever%" OR LOWER(efo_term) LIKE "%fever%") AND (LOWER(drugName) LIKE "%ziconotide%" OR LOWER(tradeNames_list) LIKE "%ziconotide%" OR LOWER(syns_list) LIKE "%ziconotide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_891740', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891746', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891748', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891750', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891754', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891756', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891758', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891762', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891764', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891766', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891768', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914652', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914654', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914656', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914658', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914660', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914662', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914664', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914666', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914668', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914670', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914674', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914676', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914678', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914680', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914682', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914686', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914688', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914672', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891760', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891744', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891736', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891732', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891730', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914684', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914650', 'drugName': 'Ziconotide', 'tradeNames_list': "['Prialt']", 'syns_list': "['.omega.-conotoxin m viia', 'SNX-111', 'Ziconotide']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891752', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891742', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891738', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_891734', 'drugName': 'Ziconotide Acetate', 'tradeNames_list': "['Prialt']", 'syns_list': "['Ziconotide acetate']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1576 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of renal cell carcinoma? | In the context of renal cell carcinoma, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal cell carcinoma%" OR LOWER(efo_term) LIKE "%renal cell carcinoma%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085634', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086039', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086174', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086309', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086579', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086714', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086849', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087119', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087254', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087389', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087524', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087794', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087929', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088064', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088199', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088334', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088469', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088604', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088739', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088874', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089009', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089279', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089414', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089549', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089684', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089819', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090089', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090224', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090359', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090494', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090629', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089144', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086984', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085904', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085364', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085094', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084959', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089954', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087659', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086444', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085769', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085499', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085229', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1016 | Q34 | What are the names of the genes that are targeted by the drug Glycopyrrolate in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Glycopyrrolate targets the gene cholinergic receptor muscarinic 3 and cholinergic receptor muscarinic 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%glycopyrrolate%" OR LOWER(tradeNames_list) LIKE "%glycopyrrolate%" OR LOWER(syns_list) LIKE "%glycopyrrolate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857534', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857561', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857570', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857579', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857597', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857606', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857615', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857633', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857642', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857651', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857660', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857678', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857687', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857696', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857705', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857714', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857723', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857732', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857741', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857750', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857759', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857777', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857786', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857768', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857624', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857552', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857498', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857489', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857516', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857669', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM1', 'approvedName': 'cholinergic receptor muscarinic 1'}, {'UUID': 'DrugTargetsIndication121923_text_857588', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857543', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857525', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857507', 'drugName': 'Glycopyrrolate', 'tradeNames_list': "['Cuvposa', 'Dartisla odt', 'Glycopyrrolate', 'Glyrx-pfLonhala magnair kit', 'Robinul', 'Robinul forte', 'Robinul fte', 'SeebriSialanar']", 'syns_list': "['AD-237', 'AHR-504', 'CHF-5259', 'CHF5259', 'GlycopyrrolateGlycopyrrolate, erythro-', 'Glycopyrrone bromideGlycopyrronium (as bromide)', 'Glycopyrronium bromide', 'NSC-250836NSC-251251', 'NSC-251252', 'NVA-237', 'NVA237', 'Nodapton', 'ORG-NC-45PT-001', 'PT001', 'Robanul', 'Tarodyl', 'Tarodyn']", 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1738 | Q34 | What are the names of the genes that are targeted by the drug Patisiran Sodium in the treatment of amyloidosis? | In the context of amyloidosis, the drug Patisiran Sodium targets the gene transthyretin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%amyloidosis%" OR LOWER(efo_term) LIKE "%amyloidosis%") AND (LOWER(drugName) LIKE "%patisiran sodium%" OR LOWER(tradeNames_list) LIKE "%patisiran sodium%" OR LOWER(syns_list) LIKE "%patisiran sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097701', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097710', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097713', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097716', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097722', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097725', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097728', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097731', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097707', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097695', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097689', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097686', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097719', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097704', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097698', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}, {'UUID': 'DrugTargetsIndication121923_text_1097692', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'syns_list': "['Patisiran sodium']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amyloidosis', 'efo_term': 'amyloidosis', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1529 | Q34 | What are the names of the genes that are targeted by the drug Aprepitant in the treatment of post operative nausea and vomiting? | In the context of post operative nausea and vomiting, the drug Aprepitant targets the gene tachykinin receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%post operative nausea and vomiting%" OR LOWER(efo_term) LIKE "%post operative nausea and vomiting%") AND (LOWER(drugName) LIKE "%aprepitant%" OR LOWER(tradeNames_list) LIKE "%aprepitant%" OR LOWER(syns_list) LIKE "%aprepitant%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072874', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072943', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072966', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072989', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073035', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073058', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073081', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073155', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073160', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073165', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073170', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073180', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073185', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073104', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072920', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072828', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072782', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072759', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073175', 'drugName': 'Fosaprepitant Dimeglumine', 'tradeNames_list': "['Emend', 'Fosaprepitant dimeglumine']", 'syns_list': "['Fosaprepitant (as dimeglumine)', 'Fosaprepitant dimeglumineFosaprepitant meglumine', 'MK-0517']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1073012', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072897', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072851', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1072805', 'drugName': 'Aprepitant', 'tradeNames_list': "['Aprepitant', 'Cinvanti', 'Emend']", 'syns_list': "['Aprepitant', 'L-754,030', 'MK-0869', 'MK-869', 'NSC-748825']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'TACR1', 'approvedName': 'tachykinin receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.200 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of pemphigus? | In the context of pemphigus, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pemphigus%" OR LOWER(efo_term) LIKE "%pemphigus%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218082', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218478', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218498', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218686', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218894', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218914', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219102', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219310', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219330', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219518', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219538', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219746', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219934', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219954', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220142', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220162', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220350', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220370', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220558', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220578', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220766', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220786', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219122', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218290', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217874', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217666', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217646', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219726', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218706', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218270', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218062', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217854', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pemphigus', 'efo_term': 'pemphigus vulgaris', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.16 | Q34 | What are the names of the genes that are targeted by the drug Cyclobenzaprine Hydrochloride in the treatment of Muscle spasm? | In the context of Muscle spasm, the drug Cyclobenzaprine Hydrochloride targets the gene 5-hydroxytryptamine receptor 2C and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscle spasm%" OR LOWER(efo_term) LIKE "%muscle spasm%") AND (LOWER(drugName) LIKE "%cyclobenzaprine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cyclobenzaprine hydrochloride%" OR LOWER(syns_list) LIKE "%cyclobenzaprine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_151278', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151296', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151302', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151308', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151320', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151326', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151332', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151344', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151350', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151356', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151362', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151374', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151380', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151386', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151392', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151398', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151404', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151410', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151416', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151422', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151428', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151434', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151338', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151290', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151266', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151254', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151248', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151368', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151314', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151284', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151272', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_151260', 'drugName': 'Cyclobenzaprine Hydrochloride', 'tradeNames_list': "['Amrix', 'Cyclobenzaprine hydrochloride', 'Flexeril']", 'syns_list': "['Cyclobenzaprine hcl', 'Cyclobenzaprine hydrochloride', 'MK-130MK-130 HYDROCHLORIDE', 'MK-130 [AS THE BASE]', 'NSC-169900', 'NSC-173379NSC-78206']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spasm', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.267 | Q34 | What are the names of the genes that are targeted by the drug Budesonide in the treatment of Rhinitis, Allergic, Perennial? | In the context of Rhinitis, Allergic, Perennial, the drug Budesonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rhinitis, allergic, perennial%" OR LOWER(efo_term) LIKE "%rhinitis, allergic, perennial%") AND (LOWER(drugName) LIKE "%budesonide%" OR LOWER(tradeNames_list) LIKE "%budesonide%" OR LOWER(syns_list) LIKE "%budesonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222618', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222753', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222798', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222843', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222933', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222978', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223023', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223113', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223158', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223203', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223248', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223338', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223383', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223428', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223473', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223518', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223563', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223608', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223653', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223698', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223743', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223833', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223878', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223923', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223968', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224013', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224103', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224148', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224193', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224238', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224283', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224328', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224373', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224418', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224463', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224508', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224553', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224598', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224643', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224688', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224733', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224778', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224823', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224868', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224913', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224958', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225003', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225048', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225093', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225138', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225183', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225273', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225318', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225363', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225408', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225228', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223788', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222708', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222528', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222438', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222393', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223068', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_224058', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_223293', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222888', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222663', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222573', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222483', 'drugName': 'Budesonide', 'tradeNames_list': "['Aircort', 'Budeflam aquanase', 'Budelin novolizer', 'BudenofalkBudesonide', 'Cortiment', 'Duoresp spiromax', 'Entocort', 'Entocort crEntocort ec', 'Ortikos', 'Preferid', 'Pulmaxan', 'PulmicortPulmicort flexhaler', 'Pulmicort l.s.', 'Pulmicort respules', 'RhinocortRhinocort allergy', 'Rhinocort aqua', 'Rhinocort aqua 64', 'SymbicortTarpeyo', 'Uceris']", 'syns_list': "['Budesonide', 'MAP-0010', 'MAP0010', 'NSC-757788', 'R01AD05', 'S-1320']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Perennial', 'efo_term': 'Rhinitis, Allergic, Perennial', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.981 | Q34 | What are the names of the genes that are targeted by the drug Abemaciclib in the treatment of cancer? | In the context of cancer, the drug Abemaciclib targets the gene cyclin dependent kinase 4 and cyclin dependent kinase 6. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%abemaciclib%" OR LOWER(tradeNames_list) LIKE "%abemaciclib%" OR LOWER(syns_list) LIKE "%abemaciclib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_849247', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851287', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850270', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849301', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849199', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851032', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849505', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851137', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849913', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850063', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850372', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849553', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850678', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851086', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850729', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849349', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851134', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849655', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851236', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850780', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849403', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849097', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849811', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849250', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850015', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849961', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850117', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850573', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850318', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850471', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849298', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850675', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850576', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850474', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850777', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850627', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849607', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849145', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849196', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851188', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849352', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851035', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849658', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849604', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851239', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850981', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850933', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850831', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849400', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850726', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850828', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849706', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849760', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849757', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849859', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849148', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849451', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850216', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849910', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850012', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849964', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850168', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850066', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850165', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849502', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850882', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850267', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850369', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850321', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850525', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850423', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850522', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851185', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850879', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849556', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850930', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850219', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849862', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849808', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849709', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851290', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851083', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850624', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849454', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850114', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_850420', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_850984', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_849094', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849234', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849391', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849392', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849693', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849238', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849393', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849394', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849139', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849239', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849395', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849140', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Endometrial Neoplasms', 'efo_term': 'endometrial cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_849240', 'drugName': 'Abemaciclib', 'tradeNames_list': "['Verzenio', 'Verzenios']", 'syns_list': "['Abemaciclib', 'LY-2835219', 'LY2835219', 'Ly-2835219']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1580 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of pancreatic neuroendocrine tumor? | In the context of pancreatic neuroendocrine tumor, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pancreatic neuroendocrine tumor%" OR LOWER(efo_term) LIKE "%pancreatic neuroendocrine tumor%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1085638', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086043', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086178', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086313', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086583', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086718', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086853', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087123', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087258', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087393', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087528', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087798', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087933', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088068', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088203', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088338', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088473', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088608', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088743', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088878', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089013', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089283', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089418', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089553', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089688', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089823', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090093', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090228', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090363', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090498', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1090633', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089148', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086988', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085908', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085368', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085098', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084963', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089958', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087663', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086448', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085773', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085503', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085233', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1299 | Q34 | What are the names of the genes that are targeted by the drug Amiodarone Hydrochloride in the treatment of ventricular fibrillation? | In the context of ventricular fibrillation, the drug Amiodarone Hydrochloride targets the gene potassium voltage-gated channel subfamily H member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%ventricular fibrillation%" OR LOWER(efo_term) LIKE "%ventricular fibrillation%") AND (LOWER(drugName) LIKE "%amiodarone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%amiodarone hydrochloride%" OR LOWER(syns_list) LIKE "%amiodarone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_969594', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969566', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969559', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969580', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969587', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}, {'UUID': 'DrugTargetsIndication121923_text_969573', 'drugName': 'Amiodarone Hydrochloride', 'tradeNames_list': "['Amidox', 'Amiodarone hydrochloride', 'Amyben', 'Cordarone', 'Cordarone xCordarone x 100', 'Cordarone x 200', 'Darmil', 'Nexterone', 'Pacerone']", 'syns_list': "['Amiodar', 'Amiodarone', 'Amiodarone hcl', 'Amiodarone hydrochlorideL-3428', 'Miodaron', 'NSC-343341', 'NSC-85442', 'Ortacrone', 'RitmocardylSK&F-33134-A', 'SKF 33134-A', 'SKF-33134-A', 'Trangorex', 'VF-236']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ventricular Fibrillation', 'efo_term': 'ventricular fibrillation', 'approvedSymbol': 'KCNH2', 'approvedName': 'potassium voltage-gated channel subfamily H member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1468 | Q34 | What are the names of the genes that are targeted by the drug Diroximel Fumarate in the treatment of immune system disease? | In the context of immune system disease, the drug Diroximel Fumarate targets the gene kelch like ECH associated protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%diroximel fumarate%" OR LOWER(tradeNames_list) LIKE "%diroximel fumarate%" OR LOWER(syns_list) LIKE "%diroximel fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055622', 'drugName': 'Diroximel Fumarate', 'tradeNames_list': "['Vumerity']", 'syns_list': "['ALKS 8700', 'ALKS-8700', 'ALKS8700', 'Alks 8700', 'BIIB-098', 'BIIB098Diroximel fumarate', 'RDC-5108', 'RDC5108']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055625', 'drugName': 'Diroximel Fumarate', 'tradeNames_list': "['Vumerity']", 'syns_list': "['ALKS 8700', 'ALKS-8700', 'ALKS8700', 'Alks 8700', 'BIIB-098', 'BIIB098Diroximel fumarate', 'RDC-5108', 'RDC5108']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1055628', 'drugName': 'Diroximel Fumarate', 'tradeNames_list': "['Vumerity']", 'syns_list': "['ALKS 8700', 'ALKS-8700', 'ALKS8700', 'Alks 8700', 'BIIB-098', 'BIIB098Diroximel fumarate', 'RDC-5108', 'RDC5108']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'KEAP1', 'approvedName': 'kelch like ECH associated protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1671 | Q34 | What are the names of the genes that are targeted by the drug Tazemetostat Hydrobromide in the treatment of sarcoma? | In the context of sarcoma, the drug Tazemetostat Hydrobromide targets the gene enhancer of zeste 2 polycomb repressive complex 2 subunit. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sarcoma%" OR LOWER(efo_term) LIKE "%sarcoma%") AND (LOWER(drugName) LIKE "%tazemetostat hydrobromide%" OR LOWER(tradeNames_list) LIKE "%tazemetostat hydrobromide%" OR LOWER(syns_list) LIKE "%tazemetostat hydrobromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095404', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095413', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095416', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095419', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095425', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095428', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095431', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095437', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095440', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095443', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095446', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095452', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095455', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095458', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095461', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095464', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095467', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095470', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095473', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095476', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095479', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095485', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095488', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095491', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095494', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095482', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095410', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095398', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095392', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095389', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095434', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095449', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095422', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095407', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095401', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095395', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoma', 'efo_term': 'sarcoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.587 | Q34 | What are the names of the genes that are targeted by the drug Carbamazepine in the treatment of epilepsy? | In the context of epilepsy, the drug Carbamazepine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%epilepsy%" OR LOWER(efo_term) LIKE "%epilepsy%") AND (LOWER(drugName) LIKE "%carbamazepine%" OR LOWER(tradeNames_list) LIKE "%carbamazepine%" OR LOWER(syns_list) LIKE "%carbamazepine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_633093', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632553', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632901', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632649', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632433', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633201', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632481', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632529', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632805', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632577', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632925', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632985', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632673', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633141', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632421', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633153', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632445', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633225', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632469', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633237', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632493', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632517', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632757', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632541', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632829', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632565', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632589', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632973', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632613', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632937', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632637', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633009', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632661', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633021', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632685', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633189', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632709', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633129', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632193', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633177', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632277', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633165', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632157', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633285', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632289', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633213', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632205', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633273', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632301', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633261', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633249', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632313', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632733', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632217', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632781', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632325', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632769', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632877', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632337', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632817', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632229', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632865', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632349', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632853', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632145', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633069', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632361', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632913', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632241', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632961', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632373', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632949', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632181', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633057', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632385', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632997', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632253', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633045', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632397', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633033', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632133', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633297', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_632409', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633105', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632265', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_633321', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633309', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_633081', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632889', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632793', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632745', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632721', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632505', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632169', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632841', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632625', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_633117', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_632457', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_632601', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_632697', 'drugName': 'Oxcarbazepine', 'tradeNames_list': "['Oxcarbazepine', 'Oxtellar xr', 'Trileptal']", 'syns_list': "['GP-47680', 'KIN-493', 'NSC-758693', 'Oxcarbamazepine', 'OxcarbazepineSPN-804']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy', 'efo_term': 'epilepsy', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.871 | Q34 | What are the names of the genes that are targeted by the drug Aspirin in the treatment of thrombotic disease? | In the context of thrombotic disease, the drug Aspirin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombotic disease%" OR LOWER(efo_term) LIKE "%thrombotic disease%") AND (LOWER(drugName) LIKE "%aspirin%" OR LOWER(tradeNames_list) LIKE "%aspirin%" OR LOWER(syns_list) LIKE "%aspirin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_834441', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834912', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835069', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835226', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835540', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835697', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_835854', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836011', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834755', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834127', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833813', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833656', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_835383', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_834598', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_834284', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833970', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'syns_list': "['Acetyl salicylate', 'Acetylsalicylic Acid', 'Acetylsalicylic acidAcetylsalicylic acid (who-ip)', 'Acetylsalicylicum acidumAcidum acetylsalicylicum', 'Acidum acetylsalicylicum (who-ip)', 'AspirinBAY1019036', 'Benzoic acid, 2-(acetyloxy)-', 'NSC-27223', 'NSC-406186']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.469 | Q34 | What are the names of the genes that are targeted by the drug Oxymetazoline Hydrochloride in the treatment of common cold? | In the context of common cold, the drug Oxymetazoline Hydrochloride targets the gene adrenoceptor alpha 1A, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%common cold%" OR LOWER(efo_term) LIKE "%common cold%") AND (LOWER(drugName) LIKE "%oxymetazoline hydrochloride%" OR LOWER(tradeNames_list) LIKE "%oxymetazoline hydrochloride%" OR LOWER(syns_list) LIKE "%oxymetazoline hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_417242', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417272', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417282', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417292', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417312', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417322', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417332', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417352', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417362', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417372', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417382', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417402', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417412', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417422', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417432', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417442', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417452', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417462', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417472', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417482', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417492', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417512', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417522', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417532', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417542', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417552', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417572', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417582', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417592', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417602', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417612', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417622', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417632', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417642', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417652', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417662', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417672', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417682', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417692', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417702', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417712', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417722', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417732', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417742', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417752', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417762', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417772', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417782', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417792', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417802', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417812', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417832', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417842', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417852', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417862', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417872', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417882', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417902', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417912', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417922', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417932', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417942', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417952', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417962', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417972', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417982', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417992', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418002', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418012', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418022', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418032', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_418042', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418052', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418062', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418072', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418082', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418092', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418102', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418112', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418122', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418132', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418142', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418152', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418162', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418172', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_418182', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_417822', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_417502', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417342', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417262', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417222', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417202', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417192', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417892', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_417562', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1B', 'approvedName': 'adrenoceptor alpha 1B'}, {'UUID': 'DrugTargetsIndication121923_text_417392', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417302', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417252', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417232', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_417212', 'drugName': 'Oxymetazoline Hydrochloride', 'tradeNames_list': "['Afrazine', 'Ocuclear', 'Rhofade', 'Upneeq', 'Visine', 'Visine l.r.']", 'syns_list': "['Agn-199201', 'NSC-757254', 'Oximetazoline hydrochlorideOxymetazoline hcl', 'Oxymetazoline hydrochloride', 'SCH 9384', 'SCH-9384']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.201 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of seborrheic dermatitis? | In the context of seborrheic dermatitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seborrheic dermatitis%" OR LOWER(efo_term) LIKE "%seborrheic dermatitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218707', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219331', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219539', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219747', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220163', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220371', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220579', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220787', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219123', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218291', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217875', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217667', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219955', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218915', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218499', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218083', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Seborrheic', 'efo_term': 'seborrheic dermatitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1194 | Q34 | What are the names of the genes that are targeted by the drug Avapritinib in the treatment of gastrointestinal stromal tumor? | In the context of gastrointestinal stromal tumor, the drug Avapritinib targets the gene KIT proto-oncogene, receptor tyrosine kinase and platelet derived growth factor receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastrointestinal stromal tumor%" OR LOWER(efo_term) LIKE "%gastrointestinal stromal tumor%") AND (LOWER(drugName) LIKE "%avapritinib%" OR LOWER(tradeNames_list) LIKE "%avapritinib%" OR LOWER(syns_list) LIKE "%avapritinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_934052', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934070', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934076', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934082', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934094', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934100', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934106', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934118', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934124', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934130', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934136', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934148', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934154', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934160', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934166', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934172', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934178', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934184', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934190', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934196', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934202', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934214', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934220', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934226', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934232', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934238', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934250', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934256', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934262', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934268', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934208', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934112', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934064', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934040', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934028', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934022', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934244', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_934142', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934088', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934058', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934046', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_934034', 'drugName': 'Avapritinib', 'tradeNames_list': "['Ayvakit']", 'syns_list': "['70C366', 'Avapritinib', 'BLU-285', 'C-366', 'X-720776', 'X720776']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastrointestinal Stromal Tumors', 'efo_term': 'gastrointestinal stromal tumor', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1044 | Q34 | What are the names of the genes that are targeted by the drug Levetiracetam in the treatment of Bilateral tonic-clonic seizure? | In the context of Bilateral tonic-clonic seizure, the drug Levetiracetam targets the gene calcium voltage-gated channel subunit alpha1 B and synaptic vesicle glycoprotein 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bilateral tonic-clonic seizure%" OR LOWER(efo_term) LIKE "%bilateral tonic-clonic seizure%") AND (LOWER(drugName) LIKE "%levetiracetam%" OR LOWER(tradeNames_list) LIKE "%levetiracetam%" OR LOWER(syns_list) LIKE "%levetiracetam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_914950', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915082', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915126', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915170', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915258', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915302', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915346', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915434', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915478', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915522', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915566', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915654', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915698', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915742', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915786', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915830', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915874', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915918', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915962', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916006', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916050', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916138', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916182', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916226', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916270', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916314', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916402', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916446', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916490', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916534', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916578', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916622', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916666', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916710', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916754', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916798', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916842', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916886', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916930', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916974', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917018', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917062', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917106', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917150', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917194', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917238', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917282', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917326', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917370', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917414', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917458', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917546', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917590', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917634', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917678', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917722', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917766', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917854', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917898', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917942', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917986', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918030', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918074', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918118', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918162', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918206', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917502', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916094', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915390', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915038', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914862', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914774', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914730', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_917810', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916358', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915610', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915214', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914994', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914906', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914818', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'Bilateral tonic-clonic seizure', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1120 | Q34 | What are the names of the genes that are targeted by the drug Levothyroxine Sodium in the treatment of thyroid cancer? | In the context of thyroid cancer, the drug Levothyroxine Sodium targets the gene thyroid hormone receptor alpha and thyroid hormone receptor beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid cancer%" OR LOWER(efo_term) LIKE "%thyroid cancer%") AND (LOWER(drugName) LIKE "%levothyroxine sodium%" OR LOWER(tradeNames_list) LIKE "%levothyroxine sodium%" OR LOWER(syns_list) LIKE "%levothyroxine sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924836', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924857', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924864', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924871', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924885', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924892', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924899', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924913', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924920', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924927', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924934', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924948', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924955', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924962', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924969', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924976', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924983', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924990', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924997', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925004', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925011', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925025', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925032', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925039', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925046', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925053', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925067', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925074', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925081', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925088', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925095', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925102', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925109', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925116', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925123', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925130', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925137', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925144', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925151', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925158', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925165', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925172', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925179', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925186', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925193', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925200', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925207', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925214', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925221', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925228', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925235', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925249', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925256', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925263', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925270', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925277', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925284', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925298', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925305', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925312', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925319', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925326', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925333', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925340', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925347', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925354', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925361', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925368', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925375', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925382', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925389', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925396', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925403', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925410', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925417', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925424', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925431', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925438', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925445', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925452', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925459', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925466', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925473', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925480', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925487', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925494', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925242', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925018', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924906', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924850', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924822', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924808', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924801', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925291', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925060', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924941', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924878', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924843', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924829', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924815', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1285 | Q34 | What are the names of the genes that are targeted by the drug Selpercatinib in the treatment of cancer? | In the context of cancer, the drug Selpercatinib targets the gene ret proto-oncogene, coiled-coil domain containing 6 and kinesin family member 5B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%selpercatinib%" OR LOWER(tradeNames_list) LIKE "%selpercatinib%" OR LOWER(syns_list) LIKE "%selpercatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_944390', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944401', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944404', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944408', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944415', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944418', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944422', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944429', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944432', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944436', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944439', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944446', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944450', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944453', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944457', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944460', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944464', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944467', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944471', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944474', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944478', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944485', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944488', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944492', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944495', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944499', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944506', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944509', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944513', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944516', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944520', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944523', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944527', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944530', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944534', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944537', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944541', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944544', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944548', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944551', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944555', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944558', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944562', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944565', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944569', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944572', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944576', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944579', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944583', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944586', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944590', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944597', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944600', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944604', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944607', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944611', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944614', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944621', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944625', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944628', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944632', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944635', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944639', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944642', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944646', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944649', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944653', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944656', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944660', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944663', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944667', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944670', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944674', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944677', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944681', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944684', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944688', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944691', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944695', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944698', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944702', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944705', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944709', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944712', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944716', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944719', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944593', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944481', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944425', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944397', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944383', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944376', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944373', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944618', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944502', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944443', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944411', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944394', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944387', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944380', 'drugName': 'Selpercatinib', 'tradeNames_list': "['Retevmo']", 'syns_list': "['LOXO-292', 'LY-3527723', 'LY3527723', 'Loxo-292', 'Ret inhibitor loxo-292Selpercatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.818 | Q34 | What are the names of the genes that are targeted by the drug Indomethacin in the treatment of eye inflammation? | In the context of eye inflammation, the drug Indomethacin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye inflammation%" OR LOWER(efo_term) LIKE "%eye inflammation%") AND (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_list) LIKE "%indomethacin%" OR LOWER(syns_list) LIKE "%indomethacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828375', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828477', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828511', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828545', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828443', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828307', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828239', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828205', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828579', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828409', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828341', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828273', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1556 | Q34 | What are the names of the genes that are targeted by the drug Macitentan in the treatment of hypertension? | In the context of hypertension, the drug Macitentan targets the gene endothelin receptor type A and endothelin receptor type B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%macitentan%" OR LOWER(tradeNames_list) LIKE "%macitentan%" OR LOWER(syns_list) LIKE "%macitentan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084009', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084029', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083959', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084038', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083988', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084018', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083999', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084008', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084028', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083989', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083949', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083958', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084039', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084019', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083978', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083998', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083968', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083948', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083979', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083969', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083966', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083994', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083996', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083956', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083974', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084004', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084006', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083954', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083944', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083976', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083964', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1083984', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084024', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083946', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084026', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1083986', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084034', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084036', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084014', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084016', 'drugName': 'Macitentan', 'tradeNames_list': "['Opsumit']", 'syns_list': "['ACT 064992', 'ACT-064992', 'Macitentan']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1385 | Q34 | What are the names of the genes that are targeted by the drug Clonidine in the treatment of migraine disorder? | In the context of migraine disorder, the drug Clonidine targets the gene adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%clonidine%" OR LOWER(tradeNames_list) LIKE "%clonidine%" OR LOWER(syns_list) LIKE "%clonidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1033833', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033938', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1033973', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1034008', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1033903', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033763', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1033693', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1033658', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}, {'UUID': 'DrugTargetsIndication121923_text_1034043', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B'}, {'UUID': 'DrugTargetsIndication121923_text_1033868', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033798', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C'}, {'UUID': 'DrugTargetsIndication121923_text_1033728', 'drugName': 'Clonidine', 'tradeNames_list': "['Catapres', 'Catapres-tts-1', 'Catapres-tts-2', 'Catapres-tts-3', 'ClonidineNexiclon xr']", 'syns_list': "['Catapres', 'Catarpres-tts', 'Clonidine', 'Clonidine extended releaseClorpres', 'Combipres', 'Duraclon', 'ST-155-BS', 'ST-155BS']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1398 | Q34 | What are the names of the genes that are targeted by the drug Siponimod Fumarate in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Siponimod Fumarate targets the gene sphingosine-1-phosphate receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%siponimod fumarate%" OR LOWER(tradeNames_list) LIKE "%siponimod fumarate%" OR LOWER(syns_list) LIKE "%siponimod fumarate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1036789', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036792', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036793', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036794', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036796', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036797', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036798', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036800', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036801', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036799', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036791', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036785', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036784', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036787', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036795', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036790', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Chronic Progressive', 'efo_term': 'chronic progressive multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036788', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis, Relapsing-Remitting', 'efo_term': 'relapsing-remitting multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036786', 'drugName': 'Siponimod Fumarate', 'tradeNames_list': "['Mayzent']", 'syns_list': "['NVP-BAF312-AEA', 'Siponimod fumarate', 'Siponimod fumaric acidSiponimod hemifumarate', 'Siponimod hemifumaric acid']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1665 | Q34 | What are the names of the genes that are targeted by the drug Spironolactone in the treatment of nephrotic syndrome? | In the context of nephrotic syndrome, the drug Spironolactone targets the gene nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nephrotic syndrome%" OR LOWER(efo_term) LIKE "%nephrotic syndrome%") AND (LOWER(drugName) LIKE "%spironolactone%" OR LOWER(tradeNames_list) LIKE "%spironolactone%" OR LOWER(syns_list) LIKE "%spironolactone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094545', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094659', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094621', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094469', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094355', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094393', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094583', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094507', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1094431', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'syns_list': "['NSC-150399', 'SC-9420', 'Spironolactone', 'Spironolactone cevaSpironolactonum', 'Verospirone']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.547 | Q34 | What are the names of the genes that are targeted by the drug Olopatadine Hydrochloride in the treatment of allergic conjunctivitis? | In the context of allergic conjunctivitis, the drug Olopatadine Hydrochloride targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic conjunctivitis%" OR LOWER(efo_term) LIKE "%allergic conjunctivitis%") AND (LOWER(drugName) LIKE "%olopatadine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%olopatadine hydrochloride%" OR LOWER(syns_list) LIKE "%olopatadine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455975', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455959', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455955', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455967', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455971', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455963', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'syns_list': "['ALO-4943A', 'ALO4943A', 'Allelock', 'KW-4679', 'KW4679Olopatadine (as hydrochloride)', 'Olopatadine hclOlopatadine hydrochloride']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.44 | Q34 | What are the names of the genes that are targeted by the drug Aripiprazole in the treatment of bipolar I disorder? | In the context of bipolar I disorder, the drug Aripiprazole targets the gene dopamine receptor D2, 5-hydroxytryptamine receptor 2A and 5-hydroxytryptamine receptor 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar i disorder%" OR LOWER(efo_term) LIKE "%bipolar i disorder%") AND (LOWER(drugName) LIKE "%aripiprazole%" OR LOWER(tradeNames_list) LIKE "%aripiprazole%" OR LOWER(syns_list) LIKE "%aripiprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_158029', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158047', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158053', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158059', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158071', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158077', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158083', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158095', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158101', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158107', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158113', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158125', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158131', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158137', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158143', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158149', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158155', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158161', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158167', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158173', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158179', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158191', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158197', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158203', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158209', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158215', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158227', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158233', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158239', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158245', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158251', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158257', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158263', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158269', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158275', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158281', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158287', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158293', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158299', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158305', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158311', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158317', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158323', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158329', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158335', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158341', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158347', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158353', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158359', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158365', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158371', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158383', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158389', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158395', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158401', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158407', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158413', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158425', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158431', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158437', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158443', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158449', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158455', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158461', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158467', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158473', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158479', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158485', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158491', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158497', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158503', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158509', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158515', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158521', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158527', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158533', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158539', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158545', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158551', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158557', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158563', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158569', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158575', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158581', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158587', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158593', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158377', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158185', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158089', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158041', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158017', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158005', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_157999', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158419', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_158221', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158119', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158065', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158035', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158023', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_158011', 'drugName': 'Aripiprazole Lauroxil', 'tradeNames_list': "['Aristada', 'Aristada initio kit']", 'syns_list': "['ALKS 9072', 'ALKS-9070', 'ALKS-9072', 'Aripiprazole lauroxilAristada initio', 'RDC-3317', 'RDC3317']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.276 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Furoate in the treatment of chronic obstructive pulmonary disease? | In the context of chronic obstructive pulmonary disease, the drug Fluticasone Furoate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chronic obstructive pulmonary disease%" OR LOWER(efo_term) LIKE "%chronic obstructive pulmonary disease%") AND (LOWER(drugName) LIKE "%fluticasone furoate%" OR LOWER(tradeNames_list) LIKE "%fluticasone furoate%" OR LOWER(syns_list) LIKE "%fluticasone furoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_225659', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225686', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225695', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225704', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225722', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225731', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225740', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225758', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225767', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225776', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225785', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225803', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225812', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225821', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225830', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225839', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225848', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225857', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225866', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225875', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225884', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225902', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225911', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225920', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225929', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225938', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225956', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225965', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225974', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225983', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225992', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226001', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226010', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226019', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226028', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226037', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226046', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226055', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226064', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226073', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226082', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226091', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226100', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225893', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225749', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225677', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225641', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225623', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225614', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225947', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225794', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225713', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225668', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225650', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_225632', 'drugName': 'Fluticasone Furoate', 'tradeNames_list': "['Arnuity ellipta', 'Avamys', 'Flonase sensimist allergy reliefRelvar ellipta', 'Trelegy ellipta', 'Veramyst']", 'syns_list': "['Allermist', 'Ennhale', 'Fluticasone furoate', 'Furamist', 'GSK 685 698GSK-685968', 'GSK685968', 'GW-685698X', 'GW685698X']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Disease, Chronic Obstructive', 'efo_term': 'chronic obstructive pulmonary disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1252 | Q34 | What are the names of the genes that are targeted by the drug Armodafinil in the treatment of narcolepsy-cataplexy syndrome? | In the context of narcolepsy-cataplexy syndrome, the drug Armodafinil targets the gene solute carrier family 6 member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%narcolepsy-cataplexy syndrome%" OR LOWER(efo_term) LIKE "%narcolepsy-cataplexy syndrome%") AND (LOWER(drugName) LIKE "%armodafinil%" OR LOWER(tradeNames_list) LIKE "%armodafinil%" OR LOWER(syns_list) LIKE "%armodafinil%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939102', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939159', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939178', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939197', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939235', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939254', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939273', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939311', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939330', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939349', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939368', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939140', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939064', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939026', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939007', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939292', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939216', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939121', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939083', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}, {'UUID': 'DrugTargetsIndication121923_text_939045', 'drugName': 'Armodafinil', 'tradeNames_list': "['Armodafinil', 'Nuvigil']", 'syns_list': "['Armodafinil', 'CEP-10952', 'CEP-10953', 'CRL-40982', 'Modafinil, (r)-NSC-751850', 'NSC-758711', 'R-(-)-modafinil']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Narcolepsy', 'efo_term': 'narcolepsy-cataplexy syndrome', 'approvedSymbol': 'SLC6A3', 'approvedName': 'solute carrier family 6 member 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.103 | Q34 | What are the names of the genes that are targeted by the drug Ondansetron in the treatment of Nausea and vomiting? | In the context of Nausea and vomiting, the drug Ondansetron targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nausea and vomiting%" OR LOWER(efo_term) LIKE "%nausea and vomiting%") AND (LOWER(drugName) LIKE "%ondansetron%" OR LOWER(tradeNames_list) LIKE "%ondansetron%" OR LOWER(syns_list) LIKE "%ondansetron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205897', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205902', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205903', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205937', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205941', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205942', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205943', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205980', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205981', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205982', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205983', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205901', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205862', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205860', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205857', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205977', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205940', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205900', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205863', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Radiation-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205861', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.